Anopheles salivary antigens as serological biomarkers of 1

vector exposure and malaria transmission: A systematic 2

review with multilevel modelling 3

- Ellen A Kearney^{1,2}, Paul A Agius^{1,2,3}, Victor Chaumeau^{4,5}, Julia C Cutts^{1,6}, Julie A Simpson², Freya JI 4 5 Fowkes1,2,3*
- 6 ¹ The McFarlane Burnet Institute of Medical Research and Public Health, Melbourne, Victoria, 7 Australia
- 8 ² Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The
- 9 University of Melbourne, Melbourne, Victoria, Australia
- ³ Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, 10 11 Australia
- 12 ⁴ Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical
- 13 Medicine, Mahidol University, Mae Sot, Thailand
- ⁵ Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of 14
- Oxford, Oxford, United Kingdom 15
- 16 ⁶ Department of Medicine at the Doherty Institute, The University of Melbourne, Melbourne, Victoria,
- 17 Australia
- 18 * Corresponding author:
- 19 Email: freya.fowkes@burnet.edu.au (FJIF)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 Abstract

Background: Entomological surveillance for malaria is inherently resource-intensive and produces crude population-level measures of vector exposure which are insensitive in low-transmission settings. Antibodies against *Anopheles* salivary proteins measured at the individual-level may serve as proxy biomarkers for vector exposure and malaria transmission, but their relationship is yet to be quantified.

Methods: A systematic review of studies measuring antibodies against *Anopheles* salivary antigens
 (PROSPERO: CRD42020185449). Multilevel modelling estimated associations between
 seroprevalence with *Anopheles* human biting rate (HBR) and malaria transmission measures.

28 Results: From 3981 studies identified in literature searches, 42 studies across 16 countries were 29 included contributing 393 meta-observations of anti-Anopheles salivary antibodies determined in 30 42,764 samples. A positive non-linear association between HBR and seroprevalence was found; overall 31 a 50% increase in HBR was associated with a 13% increase in odds of seropositivity (OR: 1.13, 95% CI: 32 1.06-1.20, p<0.001). The association between HBR and Anopheles salivary antibodies was strongest 33 with concordant, rather than discordant Anopheles species. Seroprevalence was also significantly 34 positively associated with established epidemiological measures of malaria transmission: entomological 35 inoculation rate, *Plasmodium* spp. prevalence, and malarial endemicity class.

36 **Conclusions:** *Anopheles* salivary antibody biomarkers can serve as a proxy measure for HBR and 37 malaria transmission, and could monitor vectorial capacity and malaria receptivity of a population to 38 sustain malaria transmission. Validation of *Anopheles* species-specific biomarkers are important given 39 the global heterogeneity in the distribution of *Anopheles* species. Salivary biomarkers have the potential 40 to transform surveillance by replacing impractical, inaccurate entomological investigations, especially 41 in areas progressing towards malaria elimination.

42 Funding: Australian National Health and Medical Research Council, Wellcome Trust.

43

44 Introduction

45 Sensitive and accurate tools to measure and monitor changes in malaria transmission are essential to track progress towards malaria control and elimination goals. Currently, the gold standard measurement 46 47 of malaria transmission intensity is the entomological inoculation rate (EIR), a population-measure 48 defined as the number of infective Anopheles mosquito bites a person receives per unit of time. EIR is 49 calculated as the human biting rate (HBR; measured at the population-level by entomological vector-50 sampling methodologies (gold standard: human landing catch)) multiplied by the sporozoite index 51 (proportion of captured Anopheles with sporozoites present in their salivary glands). However, 52 estimation of EIR and HBR via entomological investigations are inherently labour and resource 53 intensive, requiring trained collectors, specialised laboratories and skilled entomologists. Furthermore, 54 these approaches provide a crude population-level measure of total vector exposure at a particular time 55 and location, precluding investigation of heterogeneity and natural transmission dynamics of individual-56 level vector-human interactions [1]. For example, indoor human landing catches provide poor estimates 57 of outdoor biting and thus total vector exposure [2]. The sensitivity of EIR is further compromised in 58 low transmission settings where the number of *Plasmodium*-infected specimens detected is low and 59 often zero.

60 Evaluation of the human antibody response to Anopheles spp. salivary proteins has the potential to be 61 a logistically practical approach to estimate levels of exposure to vector bites at an individual-level. 62 Several Anopheles salivary proteins have been shown to be immunogenic in individuals naturally 63 exposed to the bites of Anopheles vectors and have been investigated as serological biomarkers to 64 measure Anopheles exposure [3-11], malaria transmission [12-14] and as an outcome for vector control intervention studies [4-6, 14, 15]. However, a major short-coming of the literature is that studies are 65 66 largely descriptive and do not quantify the association between entomological and malariometric 67 measures and anti-Anopheles salivary antibody responses. We undertook a systematic review with multilevel modelling, to quantify the association between HBR, EIR, and other markers of malaria 68 69 transmission, with anti-Anopheles salivary antibody responses and to understand how these associations

vary according to transmission setting and dominant *Anopheles* vectors. This knowledge is pertinent to
advance the use of salivary antibody biomarkers as a vector and malaria transmission sero-surveillance
tool.

73 Methodology

74 Search strategy and selection criteria

We performed a systematic review with multilevel modelling according to the MOOSE and PRISMA guidelines [16, 17] (Reporting Standards Document). Five databases were searched for published studies investigating antibodies to *Anopheles* salivary antigens as a biomarker for mosquito exposure or malaria transmission published before 30th of June 2020. The protocol (Supplementary File 1) was registered with PROSPERO (CRD42020185449).

The primary criteria for inclusion in this systematic review was the reporting of estimates of seroprevalence or total levels of Immunoglobulin (Ig) in human sera against *Anopheles* salivary antigens. We considered for inclusion: cross-sectional, cohort, intervention and case-control studies of individuals or populations living in all geographies with natural exposure to *Anopheles* mosquitoes. Studies that were solely performed in participants not representative of the wider naturally exposed population (*i.e.* mosquito allergic patients, soldiers, returned travellers) were excluded.

86 Measures

87 **Outcomes**

The primary outcome of our systematic review was antibodies (seroprevalence or levels, including all Ig isotypes and subclasses) against any *Anopheles* salivary antigens (full-length recombinant proteins, peptides and crude salivary extract). As measurement of antibody levels does not produce a common metric between studies only values of seroprevalence could be included in multilevel modelling analyses. Therefore, to maximise data, authors of studies that reported only antibody levels were contacted and asked to classify their participants as 'responders' or 'non-responders' according to

94 seropositivity (antibody level relative to unexposed sera). Studies that provided antibody levels or 95 categorised seropositivity based upon arbitrary cut offs are included in narrative terms only.

96 **Exposures**

97 The primary exposures of interest were the entomological metrics HBR (average number of bites 98 received per person per night) and EIR (infectious bites received per person per year). Secondary 99 exposures included study-reported prevalence of *Plasmodium* spp. infection (confirmed by either 100 microscopy, rapid diagnostic test, or polymerase chain reaction (PCR)) and seroprevalence of 101 antimalarial antibodies against pre-erythrocytic and blood-stage *Plasmodium* spp. antigens. Where 102 exposure estimates were not provided, we attempted to source data from other publications by the 103 authors, or using the site geolocation and year to obtain estimates of EIR from the Pangaea dataset [18], 104 P. falciparum rates in 2-10 year olds (PfPR₂₋₁₀) and dominant vector species (DVS) from the Malaria 105 Atlas Project (MAP) [19]. Malarial endemicity classes were derived by applying established endemicity 106 cut-offs to $P_f PR_{2-10}$ estimates [20]. For the purposes of the modelling analyses we defined DVS as where 107 An. gambiae sensu lato (s.l.) was the only DVS, where An. gambiae s.l., was present with additional 108 DVS, or where An. gambiae s.l. was absent. Studies of salivary antigens where exposure variables could 109 not be sourced and data could not be extracted were excluded.

110 Statistical analysis

111 Where seroprevalence estimates of antibodies against the same salivary antigen and exposure of interest 112 were reported in more than one study, generalised multilevel (mixed-effects, logistic) modelling was 113 used to quantify associations between the exposures of interest and salivary antibody seroprevalence 114 measurements [21]. Random intercepts for study and country were included to account for nested 115 dependencies induced from multiple meta-observations (level one) from the same study (level two) and 116 multiple studies from the same country (level three). Additionally, a random slope for the entomological 117 and malariometric exposure parameters was included to model study-specific heterogeneity in the effect 118 of the exposure of interest (HBR/EIR/malaria prevalence/antimalarial antibody seroprevalence). The 119 associations between the various exposures and the different salivary antigens were analysed separately,

however estimates of IgG seroprevalence against the recombinant full-length protein (gSG6) and synthetic peptide (gSG6-P1, the one peptide determined in all studies utilising peptides) form of the gSG6 antigen were analysed together.

Potential effect modification of the associations between exposures and anti-*Anopheles* salivary antibody responses were explored. In analyses quantifying the associations between HBR, as well as EIR, and seropositivity, we included an interaction term with DVS and for vector collection method (human landing catch or other indirect measures *e.g.* light traps, spray catches, etc.). For the association between *Plasmodium* spp. prevalence and seropositivity, interaction terms with malaria detection methodology (light microscopy or PCR) and malarial species (*P. falciparum* only, or *P. falciparum* and *P. vivax*) were estimated.

The natural log of the exposure measures (HBR, EIR, malaria prevalence and antimalarial antibody seroprevalence) were estimated in modelling to account for their non-linear associations with seroprevalence. Intraclass correlation coefficients (ICCs) were estimated for country- and studyspecific heterogeneity using estimated model variance components. All statistical analyses were performed using STATA v15.1.

135 **Risk of bias in individual studies**

Risk of bias was assessed by one reviewer using the Risk of Bias in Prevalence Studies tool [22]. The risk of bias pertains to the reported seroprevalence estimates of anti-*Anopheles* salivary antibodies included in the multilevel modelling.

139 **Results**

Literature searches identified 158 potentially relevant studies, of which 42 studies were included in the systematic review (Figure 1) and are described in Table 1. Briefly, studies were performed in 16 countries mostly in hypo or mesoendemic areas of Africa where *An. gambiae s.l.* is a dominant vector (n=32), with a minority performed in South America (n=4), Asia (n=4), and the Pacific (n=2) where *An. gambiae s.l.* is not found. In total, our review included 393 meta-observations of anti-*Anopheles*

145 salivary antibodies determined from antibody measurements in a total of 42,764 sera samples. The 146 salivary antigen most commonly assessed was An. gambiae Salivary Gland 6 (gSG6), as a full-length 147 protein (n=8) and synthetic peptide (An. gambiae Salivary Gland 6 Peptide 1; gSG6-P1; n=24). 148 Additional salivary antigens assessed included An. gambiae gSG6-P2 (n=3), recombinant cE5 (n=2), 149 g-5'nuc (n=1), and recombinant An. funestus fSG6 (n=2) and f-5'nuc (n=1). Seven studies measured 150 antibodies to whole salivary gland extracts from An. gambiae (n=4), An. darlingi (n=2), An. albimanus 151 (n=1), and An. dirus (n=1), while one study assessed antibodies against synthetic peptides of An. albimanus (Table 1). All studies investigated total IgG and only five determined an additional isotype 152 153 or subclass [7, 23-26]. The paucity of studies investigating these latter-mentioned antibody types and 154 Anopheles salivary biomarkers precluded extensive multilevel analyses; instead, we present their associations in narrative terms in Supplementary File 5. Analyses reported below focus on quantifying 155 156 the relationships between HBR, EIR and markers of malaria transmission with total IgG to An. gambiae 157 gSG6. The distributions of exposure estimates were: HBR (median: 3.1 bites per person per night, IOR: 158 0.9-12.1; range: 0-121.4), EIR (median: 7.3 infectious bites received per person per year, IQR: 0-36.4; 159 range: 0-585.6), and *Plasmodium* spp. prevalence (median: 9.1%; IQR: 4-22%; range: 0-94.6%).

160



161

162 Figure 1. Flow diagram of study identification. Excluded studies are detailed in Figure 1 –

163 Supplement 1.

| Study year | Country | Malarial endemicity class | Dominant malaria vector species | Study design | No. participants (samples) | Meta-N | Vector and malariometric variables | Salivary antibody outcomes (Seroprevalence[%];[L]evels) |
|-----------------------|------------------|------------------------------|--|---|----------------------------------|--------|--|--|
| Africa | | | | | | | | |
| Brosseau 2012 [27] | Angola | Hypoendemic; Mesoendemic | An. funestus | Cross-sectional [‡] | (1584) | 6 | Plas+ ^{LM} ; PfPR | gSGE IgG [L] |
| Drame 2010 [5] | Angola | Hypoendemic | An. gambiae s.l. | Cohort | 105 (1470) | 12 | HBR; <i>Plas</i> + ^{LM} ; <i>Pf</i> PR | gSG6-P1 IgG [%;L] |
| Drame 2010 [6] | Angola | Hypoendemic | An. gambiae s.l. | Cohort | 109 (1279) | 12 | HBR; <i>Plas</i> + ^{LM} ; <i>Pf</i> PR | gSGE IgG [L] |
| Marie 2015 [28] | Angola | Hypoendemic | An. gambiae s.l. | Cohort | 71 (852) | 12 | HBR; <i>Pf</i> PR | gcE5 IgG [L] |
| Drame 2015 [7] | Benin | Hyperendemic | An. gambiae s.l.; An. funestus | Cohort [‡] | 133 (532) | 4 | HBR; <i>Pf</i> PR | gSG6-P1 IgG & IgM [%;L] |
| Rizzo 2011 [9] | Burkina Faso | Hyperendemic* | An. gambiae s.l. | Repeated cross- sectional | (2066) | 14 | HBR; EIR; <i>Plas</i> + ^{LM§} | gSG6 IgG [%;L] |
| Rizzo 2011 [8] | Burkina Faso | Hyperendemic* | An. gambiae s.l. | Repeated cross- sectional | 335 (335) | 3 | HBR | <i>f</i> SG6 IgG [%;L] |
| Rizzo 2014 [24] | Burkina Faso | Hyperendemic* | An. gambiae s.l. | Repeated cross- sectional | (359) | 3 | HBR | gcE5 IgG [%;L]; IgG1 & IgG [L] |
| Rizzo 2014 [25] | Burkina Faso | Hyperendemic* | An. gambiae s.l. | Repeated cross- sectional | 270 (270) | 6 | HBR | gSG6 IgG1 & IgG4 [L] |
| Soma 2018 [29] | Burkina Faso | Mesoendemic | An. gambiae s.l. | Cross-sectional | 1728 (273) | 6 | HBR; EIR; <i>Plas+</i> ^{LM} ; <i>Pf</i> PR | gSG6-P1 IgG [%;L] |
| Koffi 2015 [30] | Cote d'Ivoire | Hypoendemic; Mesoendemic | An. gambiae s.l.; An. funestus† | Cross-sectional | 94 (94) | 3 | <i>Plas</i> + ^{LM} ; <i>Pf</i> -IgG; <i>Pf</i> PR | gSG6-P1 IgG [%;L] |
| Koffi 2017 [31] | Cote d'Ivoire | Hypoendemic | An. gambiae s.l.; An. funestus [†] | Repeated cross- sectional | 234 (234) | 5 | Pf-IgG; PfPR | gSG6-P1 IgG [%;L] |
| Traoré 2018 [32] | Cote d'Ivoire | Hypoendemic | An. gambiae s.l.; An. funestus [†] | Repeated cross- sectional [‡] | 89 (178) | 4 | HBR; <i>Plas</i> + ^{LM} ; <i>Pf</i> PR | gSG6-P1 IgG [L] |
| Traoré 2019 [33] | Cote d'Ivoire | Hypoendemic | An. gambiae s.l.; An. funestus [†] | Repeated cross- sectional [‡] | (442) | 6 | HBR; <i>Plas</i> + ^{LM} ; <i>Pf</i> PR | gSG6-P1 IgG [%;L] |

Table 1: Key descriptive information from included studies

| Sadia-Kacou 2019 [34] | Cote d'Ivoire | Mesoendemic | An. gambiae s.l. | Repeated cross- sectional [‡] | 775 (775) | 8 | <i>Pf</i> PR | gSG6-P1 IgG [L] |
|--------------------------|------------------|---|--|---|----------------|----|--|--|
| Badu 2015 [35] | Ghana | Mesoendemic | An. gambiae s.l.; An. funestus† | Repeated cross- sectional [‡] | 295 (885) | 3 | <i>Plas</i> + ^{LM} ; <i>Pf</i> -IgG; <i>Pf</i> PR | gSG6-P1 IgG [%;L] |
| Badu 2012 [3] | Kenya | Hypoendemic; Mesoendemic | An. gambiae s.l. | Repeated cross- sectional | (1366) | 5 | EIR; <i>Plas</i> + ^{LM§} ; <i>Pf</i> PR | gSG6-P1 IgG [%;L] |
| Sagna 2013[36] | Senegal | Hypoendemic; Mesoendemic | An. gambiae s.l. | Cohort [‡] | 265 (1325) | 25 | HBR; <i>Plas</i> + ^{LM§} ; <i>Pf</i> PR | gSG6-P1 IgG [%;L] |
| Drame 2012 [11] | Senegal | Hypoendemic | An. gambiae s.l. | Cross-sectional | 1010 (1010) | 16 | HBR; <i>Pf</i> PR | gSG6-P1 IgG [%;L] |
| Poinsignon 2010 [37] | Senegal | Hypoendemic | An. funestus | Cohort [‡] | 87 (261) | 3 | HBR; <i>Plas</i> + ^{LM§} ; <i>Pf</i> PR | gSG6-P1 IgG [L] |
| Sarr 2012 [38] | Senegal | Hypoendemic; Mesoendemic | An. gambiae s.l.; An. funestus† | Repeated cross- sectional [‡] | (401) | 4 | HBR; <i>Plas</i> + ^{LM§} ; <i>Pf</i> - IgG; <i>Pf</i> PR | gSG6-P1 IgG [%;L] |
| Lawaly 2012 [23] | Senegal | Mesoendemic | An. gambiae s.l.; An. funestus† | Cohort | 387 (711) | 4 | HBR; <i>Plas</i> + ^{LM§} ; <i>Pf</i> PR | gSGE IgG, IgG4 & IgE [L] |
| Ali 2012 [39] | Senegal | Hypoendemic;* Mesoendemic;* Hyperendemic* | An. gambiae s.l.; An. funestus; An. pharoensis | Cross-sectional | (134) | 3 | HBR; EIR | gSG6 IgG [%;L] fSG6 IgG [%;L]; f5'nuc IgG [%;L]; g5'nuc IgG [%;L] |
| Ambrosino 2010 [40] | Senegal | Hypoendemic;* Mesoendemic;* Hyperendemic* | An. gambiae s.l.; An. funestus; An. pharoensis | Cross-sectional | (123) | 3 | EIR; Pf-IgG | gSG6-P1 IgG [%]; gSG6-P2 IgG [%] |
| Perraut 2017 [41] | Senegal | Hypoendemic; Mesoendemic | An. gambiae s.l.; An. funestus | Repeated cross- sectional | (798) | 4 | EIR; <i>Plas</i> + ^{LM} ; <i>Plas</i> + ^{PCR} ; <i>Pf</i> -IgG; <i>Pf</i> PR | gSG6-P1 IgG [%] |
| Poinsignon 2008 [42] | Senegal | Mesoendemic | An. gambiae s.l. | Cross-sectional [‡] | 241 (241) | 3 | HBR; <i>Pf</i> PR | gSG6-P1 IgG [L]; gSG6-P2 IgG [L] |
| Poinsignon 2009 [43] | Senegal | Mesoendemic | An. gambiae s.l. | Repeated cross- sectional [‡] | 61 (122) | 2 | HBR; <i>Plas</i> + ^{LM§} ; <i>Pf</i> PR | gSG6-P1 IgG [L] |
| Remoue 2006 [44] | Senegal | Mesoendemic | An. gambiae s.l. | Cross-sectional [‡] | 448 (448) | 4 | HBR; <i>Plas</i> + ^{LM§} ; <i>Pf</i> PR | gSGE IgG [%;L] |
| Sagna 2019 [45] | Senegal | Hypoendemic | An. gambiae s.l. | Cross-sectional [‡] | 809 (809) | 4 | <i>Pf</i> PR | gSG6-P1 IgG [L] |

| Stone 2012 [10] | Tanzania | Mesoendemic; Hyperendemic | An. gambiae s.l. | Cross-sectional [‡] | 636 (636) | 16 | HBR; <i>Pf</i> -IgG; <i>Pf</i> PR | gSG6 IgG [%;L] |
|-----------------------------------|--------------------|---|--|---|----------------|-----|--|---|
| Yman 2016 [46] | Tanzania | Mesoendemic; Holoendemic* | An. gambiae s.l.; An. funestus | Repeated cross- sectional [‡] | 668 (668) | 16 | <i>Pf</i> -IgG; <i>Pf</i> PR | gSG6 IgG [%] |
| Proietti 2013 [47] | Uganda | Mesoendemic | An. gambiae s.l.; An. funestus [†] | Repeated cross- sectional | 509 (509) | 3 | <i>Pf</i> -IgG; <i>Pf</i> PR | gSG6 IgG [%] |
| Americas | | | | | | | | |
| Andrade 2009 [48] | Brazil | Eliminating; Hypoendemic | An. darlingi | Cross-sectional | 204 (204) | 3 | Plas+ ^{LM¶} ; Plas+ ^{PCR¶} ; PfPR | dSGE IgG [L [∥]] |
| Londono- Renteria 2015 [12] | Colombia | | An. albimanus | Cross-sectional | 42 (42) | 2 | Plas+PCR¶ | gSG6-P1 IgG [L [∥]] |
| Londono- Renteria 2020 [49] | Colombia | Eliminating | An. albimanus | Cross-sectional | 337 (337) | 2 | Plas+ ^{PCR} ; PfPR | aPEROX-P1, P2 & P3 IgG [L]; aTRANS-P1 & P2 IgG [L] |
| Montiel 2020 [50] | Colombia | Eliminating | An. albimanus | Case-control | 113 (113) | 2 | Plas+ ^{LM} ; Plas+ ^{PCR¶} ; PfPR | gSG6-P1 IgG [L]; dSGE IgG [L]; aSTECLA SGE IgG [L]; aCartagena SGE IgG [L] |
| Asia | | | | | | | | |
| Kerkhof 2016 [51] | Cambodia | Hypoendemic | An. dirus | Cross-sectional | (8438) | 113 | <i>Plas</i> + ^{PCR} ; <i>Pf</i> -IgG; <i>Pv</i> -IgG; <i>Pf</i> PR | gSG6-P1 IgG [%;L]; gSG6-P2 IgG [%;L] |
| Charlwood 2017 [52] | Cambodia | Eliminating | An. dirus | Repeated cross- sectional | 454 (1180) | 6 | HBR; <i>Pf</i> -IgG; <i>Pf</i> PR | gSG6 IgG [L] |
| Ya-Umphan 2017 [13] | Myanmar | Eliminating | An. minimus; An. maculatus | Repeated cross- sectional | 2602 (9425) | 28 | HBR; EIR; <i>Plas+^{PCR};</i> <i>Pf</i> -IgG; <i>Pf</i> PR | gSG6-P1 IgG [%;L] |
| Waitayakul 2006 [26] | Thailand | | An. dirus | Case-control | 139 (139) | 3 | Plas+ ^{LM} | dirSGE IgG & IgM [L] |
| Pacific | | | | | | | | |
| Pollard 2019 [53] | Solomon Islands | Eliminating; Hypoendemic | An. farauti | Repeated cross- sectional | 686 (791) | 9 | HBR; EIR; <i>Pf</i> PR | gSG6-P1 IgG [%;L] |
| Idris 2017 [15] | Vanuatu | Eliminating; Hypoendemic; Mesoendemic | An. farauti | Repeated cross- sectional | 905 (905) | 3 | <i>Plas</i> + ^{LM} ; <i>Pf</i> -IgG; <i>Pv</i> -IgG; <i>Pf</i> PR | gSG6 IgG [%;L] |

- 165 Data are given as: study, year of publication, country, malarial endemicity class, malarial dominant vector species (DVS), study design (‡ indicate that study was performed solely in children),
- 166 number of participants and number of samples, number of salivary antibody outcome observations taken from study (Meta-N), entomological and malariometric indices and salivary antibody
- 167 outcomes assessed. Endemicity is derived from *P. falciparum* prevalence rate in 2-10 year olds (*Pf*PR₂₋₁₀) from Malaria Atlas Project (MAP) using site geolocations and year of study, using
- 168 established cut offs reported in Bhatt et al. [20]. If PfPR₂₋₁₀ data were not available (e.g. surveys prior to 2000; or unable to determine study site geolocation and year), endemicity class is given
- 169 as stated in the study (indicated by *). DVS is as stated in the study or extracted from MAP (indicated by †). Of note, An. gambiae sensu lato (s.l.) includes both An. gambiae sensu stricto and An.
- 170 arabiensis. Entomological and malariometric indices include human biting rate (HBR), entomological inoculation rate (EIR), prevalence estimates of *Plasmodium* spp. (*Plas+*): detected by light
- 171 microscopy (LM) or polymerase chain reaction (PCR), with § indicating prevalence of *P. falciparum* only and ¶ indicating prevalence of *P. vivax* only (no footnote indicates *P. falciparum* and *P.*
- 172 *vivax* co-endemic), as well as *Pf*PR₂₋₁₀ extracted from MAP [54]. Salivary antibody outcomes are indicated as either seroprevalence [%] or levels [L], or both [%;L], with ^{||} indicating that studies
- 173 reported results stratified by malarial infection status. Salivary antigens include recombinant full-length proteins, synthetic peptides and whole salivary gland extracts (SGE). Italicised prefix of
- 174 salivary antigen indicates species: An. gambiae (g), An. funestus (f), An. darlingi (d), An. albimanus (a), An. dirus (dir).

175 Generalised multilevel modelling of 132 meta-observations from 12 studies estimated a positive 176 association between Anopheles spp.-HBR and seroprevalence of IgG to An. gambiae gSG6 salivary 177 antigen [5, 7, 8, 10, 11, 13, 29, 33, 36, 38, 39, 53]. The magnitude of the association was such that a 178 50% relative increase in HBR was associated with a 13% increase (OR: 1.13; 95%CI: 1.06-1.20, 179 p < 0.001) in the odds of anti-gSG6 IgG seropositivity (Figure 2 and Figure 2 – Supplement 1). As the 180 association between gSG6 IgG and HBR (log transformed) is non-linear, relative change in gSG6 IgG 181 will vary across HBR levels. To quantify this, we estimated odds ratios for different incremental per 182 cent increases in HBR, shown in Figure 3A. Heterogeneity in the effect of HBR on gSG6 across studies was observed (likelihood ratio $\chi^2(1) = 109.25$, p<0.001); the 95% reference range of study-specific 183 184 effects for a 50% relative increase in HBR ranged from a 7% reduction to a 37% increase in odds (OR: 0.93-1.37). There was no evidence (p=0.443) that the association between HBR and gSG6 IgG varied 185 according to vector collection method (human landing catch or other indirect methods). However, the 186 187 magnitude of the association between An. gambiae gSG6 IgG seropositivity and HBR was greatest 188 where An. gambiae s.l. was the only dominant vector (p < 0.001); a 50% relative increase in HBR was 189 associated with a 20% increase (OR: 1.20; 95%CI: 1.11-1.31; p < 0.001) in the odds of gSG6 IgG 190 seropositivity, compared to an 8% (OR: 1.08; 95% CI: 0.99-1.18; p=0.079) and 3% (OR: 1.03; 95% CI: 191 1.02-1.05; p < 0.001) increase in odds of gSG6 IgG seropositivity where other DVS were present in 192 addition to An. gambiae s.l. and where An. gambiae s.l. was absent, respectively (Figure 4: Figure 4 – 193 Supplement 1). In order to quantify the relationship between gSG6 IgG seroprevalence and HBR, for 194 given HBR values we estimated gSG6 IgG seroprevalence by producing model-based predicted 195 probabilities overall and by DVS (Figure 4). Where An. gambiae s.l is the only DVS, predicted 196 seroprevalence of An. gambiae gSG6 ranged from 8% (95%CI: 0-22%) to 86% (95%CI: 67-100%) for 197 an HBR of 0.01 to 100 bites per person per night respectively.



198

199 Figure 2. Association between anti-gSG6 IgG seroprevalence and human biting rate (HBR). 200 Figure shows the observed anti-gSG6 IgG (either recombinant or peptide form) seroprevalence (%) and 201 HBR for each meta-observation, as well as the predicted average anti-gSG6 IgG seroprevalence 202 (predicted probability for the average study and country) with 95% confidence intervals (95%CI). 203 Circles are proportional to the size of the sample for each meta-observation. Association estimated using 204 generalised multilevel mixed-effects modelling to account for the hierarchical nature of the data, using 205 an anti-gSG6 IgG meta-observation, nested within study nested in country (model output shown in Figure 2 – Supplement 1; p < 0.001). Note: to aid visualisation the graph is truncated to show 75% of 206 HBR data (i.e. 75th percentile 12.2 bites per person per night) but HBR estimates up to 121.4 were 207 208 observed and analysed.



209

210 Figure 3. Estimated change in odds of anti-gSG6 IgG seropositivity for given per cent increases 211 in A) HBR (bites/person/night) and B) EIR (infective bites/person/year). Forest plots show estimated odds ratios (ORs) with 95% confidence intervals for given per cent increases in HBR or EIR, 212 213 estimated using generalised multilevel mixed-effects modelling of the association between anti-gSG6 IgG seropositivity and log HBR or EIR, with random-effects for country-specific and study-specific 214 215 heterogeneity in gSG6 IgG seroprevalence and study-specific heterogeneity in effect of HBR or EIR 216 (see Figure 2 – Supplement 1 and Figure 3 – Supplement 1 for model output).



Figure 4. Forest plots of predicted anti-gSG6 IgG seroprevalence (%) and *Anopheles* speciesspecific human biting rate (HBR). Panels show the predicted average anti-gSG6 IgG seroprevalence (predicted probability for the average study and country) with 95% confidence intervals for given HBR, for all *Anopheles* spp. (using model output from Figure 2 – Supplement 1) and for specific-dominant vector species (DVS): where *An. gambiae s.l.* is the only DVS, where other DVS were present in addition to *An. gambiae s.l.* and where *An. gambiae s.l.* was absent (using model output from Figure 4 – Supplement 1).

217

A positive association was also found between seroprevalence of anti-gSG6 IgG antibodies and EIR in analysis of 38 observations from eight studies (Figure 3B, Figure 3 – Supplement 1) [3, 9, 13, 29, 39-41, 53]. For a 50% increase in EIR, the odds of anti-gSG6 IgG seropositivity increased by 6% (OR: 1.06; 95%CI: 1.03-1.10; p<0.001), with heterogeneity in the study-specific effects (95% reference range: 1.00-1.13; likelihood ratio $\chi^2(1) = 15.02$, p<0.001). There was no evidence of effect modification by either vector collection method (p=0.095) or DVS (p=0.800) on the association between seroprevalence of anti-gSG6 IgG and EIR.

Similar positive associations were also found between anti-gSG6 IgG levels, HBR and EIR in 11 studies
[7-11, 29, 36, 37, 39, 42, 52] and three studies [9, 13, 39] respectively but seven studies showed no

association between HBR and levels of IgG to gSG6 [5, 13, 32, 33, 38, 43, 53].

235 The association between anti-gSG6 IgG seroprevalence and population-level prevalence of 236 Plasmodium spp. infection was investigated. Generalised multilevel modelling of 212 meta-237 observations from 14 studies [3, 5, 9, 13, 15, 29, 30, 33, 35, 36, 38, 41, 47, 51] showed that for a 10% 238 relative increase in the prevalence of *Plasmodium* spp. infection the odds of gSG6 IgG seropositivity 239 increased by 4%, although the confidence intervals were wide (OR: 1.04; 95%CI: 0.98-1.11; p=0.148) 240 (Figure 5 and Figure 5 – Supplement 1). In the association between gSG6 IgG seropositivity and 241 *Plasmodium* spp. infection, there was no evidence for a moderating effect of *Plasmodium* spp. detection method (light microscopy, or PCR, p=0.968) or species (P. falciparum and P. vivax, or P. falciparum, 242 243 p=0.586) potentially because all studies that reported *P. vivax* were co-prevalent with *P. falciparum*.



244

Figure 5. The association between anti-gSG6 IgG seroprevalence (%) and *Plasmodium* spp. 245 prevalence (%). Figure shows the observed anti-gSG6 IgG (either recombinant or peptide form) 246 247 seroprevalence (%) and prevalence of any *Plasmodium* spp. infection (%) for each meta-observation, as well as the predicted average anti-gSG6 IgG seroprevalence (predicted probability for average study) 248 249 with 95% confidence intervals (95% CI). Circles are proportional to the size of the sample for each meta-250 observation. Association estimated using generalised multilevel mixed-effects modelling to account for the hierarchical nature of the data, using an anti-gSG6 IgG meta-observation, nested within study. See 251 252 Figure 5 – Supplement 1 for model output.

253

254 Additionally, 14 studies reported estimates of anti-gSG6 IgG levels and the prevalence of *Plasmodium*

spp. infections. The median anti-gSG6 IgG antibody levels increased with increasing *Plasmodium* spp. 255

- prevalence in six of these studies [5, 13, 15, 37, 38, 51], or in Plasmodium spp. infected compared to 256
- 257 non-infected individuals [12, 50], but showed no association in eight studies [9, 29, 30, 32, 33, 35, 36,

43]. Furthermore, we also investigated associations with serological measures of malaria exposure and
found that for a 10% relative increase in pre-erythrocytic and blood-stage stage antigen seroprevalence
there was an 11% (OR: 1.11; 95% CI: 1.02-1.21%, *p*=0.013) and 5-27% (OR range: 1.05-1.27; *p* range:
<0.001 to 0.523) increase in the odds of anti-gSG6 IgG seropositivity, respectively (Supplementary File
3).

263 To give epidemiological context we estimated anti-gSG6 seroprevalence by producing model-based 264 predicted probabilities by malarial endemicity class. Multilevel modelling on 297 meta-observations 265 from 22 studies shows that the estimated anti-gSG6 IgG seroprevalence is higher for the higher endemicity classes (eliminating malaria: 20% (95%CI: 8-31%); hypoendemic: 34% (95%CI: 19-49%); 266 mesoendemic: 52% (95%CI: 35-68%); hyperendemic settings: 47% (95%CI: 27-64%); holoendemic: 267 268 78% (95%CI: 67-90%); p<0.001; Table 2). In addition, using Bayes Best-Linear-Unbiased Predictions (BLUPs) we estimated country-specific gSG6 IgG seroprevalence from an intercept only multilevel 269 model fitted to 301 meta-observations from 22 studies. It showed that IgG seroprevalence to An. 270 271 gambiae gSG6 was lowest in countries in the Pacific Region where An. gambiae is absent (Vanuatu 272 (31%) and Solomon Islands (32%)) and highest in countries where An. gambiae is a DVS (Benin (72%)) 273 and Burkina Faso (65%); Supplementary File 4).

274

275 Table 2: Association between gSG6 IgG seroprevalence (%) and malarial endemicity (*Pf*PR₂₋₁₀).

| Malaria Endemicity Class ^a | OR | 95%CI | <i>p</i> -value | Predicted gSG6 IgG seroprevalence (%) | 95%CI | |
|---|------|-------------|-----------------|--|------------|--|
| <i>Eliminating malaria</i> (<i>PfPR</i> <1%) | Ref. | | | 20.0 | 8.3, 31.7 | |
| Hypoendemic _(PfPR 1-10%) | 2.04 | 1.43, 2.90 | < 0.001 | 33.7 | 18.9, 48.5 | |
| Mesoendemic(PfPR 10-50%) | 4.19 | 2.80, 6.08 | < 0.001 | 51.5 | 34.6, 67.7 | |
| Hyperendemic(PfPR 50-75%) | 3.36 | 1.98, 5.71 | < 0.001 | 46.5 | 27.4, 63.8 | |
| Holoendemic _(PfPR >75%) | 14.4 | 9.72, 21.36 | < 0.001 | 78.2 | 66.8, 89.7 | |

Table shows the odds ratio (OR), 95% confidence interval (95%CI), p-value, as well as the predicted gSG6 IgG seroprevalence and associated 95%CI^b for associations between endemicity class (derived from *P. falciparum* parasite rates in 2-10 year olds (*Pf*PR₂₋₁₀)) and anti-gSG6 IgG seropositivity.

279a Generalised multilevel modelling estimating the association between anti-gSG6 IgG seropositivity and endemicity class with
random-effects for study-specific heterogeneity in gSG6 IgG. Model fitted to n=297 meta-observations. Endemicity class
membership is derived from $PfPR_{2-10}$ from MAP, using cut-offs taken from Bhatt *et al.* [20], or where MAP data were
unavailable, endemicity was included as indicated in the study.

^b Predicted gSG6 IgG seroprevalence (predicted probability in the average study) is estimated from generalised multilevel
 modelling

Assessments of internal and external study validity revealed there was a moderate risk of selection bias (Supplementary File 2) due to the study-specific inclusion criteria of populations at higher risk of malaria which contributed gSG6 seroprevalence estimates.

288 **Discussion**

This systematic review and multilevel modelling analysis provides the first quantification of a positive 289 290 non-linear association between seroprevalence of An. gambiae gSG6 IgG antibodies and HBR and 291 demonstrated that its magnitude varied with respect to the DVS present in the area. Importantly, this 292 review identified a paucity of studies conducted outside of Africa, as well as investigating salivary 293 antigens representing different Anopheles spp. and antigenic targets. gSG6 antibodies were positively 294 associated with the prevalence of *Plasmodium* spp. infection as well as established epidemiological 295 measures of malaria transmission: malaria endemicity class and EIR. Overall, our results demonstrate 296 that antibody seroprevalence specific for Anopheles spp. salivary antigens has the potential to be an 297 effective measure of vector exposure and malaria transmission at the population- and, potentially, individual-level. 298

299 An. gambiae gSG6 IgG seropositivity increased with increasing HBR, although these increases had 300 diminishing impact on An. gambiae gSG6 IgG seropositivity at higher levels of HBR. We also observed 301 that the association was strongest in areas where An. gambiae s.l. was the only DVS (that is concordant 302 An. gambiae species-specific HBR with An. gambiae gSG6 antibodies). Associations, albeit weaker, 303 were also observed between discordant species-specific HBR and gSG6, most likely because the An. 304 gambiae SG6 gene shares moderate sequence identity with vector species that are dominant in other 305 regions (Africa: 80% An. funestus; Asia: 79% An. stephensi and An. maculatus; 54% An. dirus; Pacific: 306 52.5% An. farauti), and is absent from the DVS of the Americas (An. albimanus and An. darlingi) [55]. 307 The generalisability of An. gambiae gSG6 IgG as a biomarker of exposure to other Anopheles spp. may 308 therefore be limited. However, our review also identified a paucity of studies investigating additional 309 salivary antigenic targets and Anopheles species not present in Africa. The identification of novel 310 salivary antigens that are species-specific will be valuable in quantifying exposure to the other

Anopheles vectors that share limited identity with *An. gambiae SG6* (such as *An. farauti* and *An. dirus*), as well as *Anopheles* spp. which lack *SG6* (as done for *An. albimanus* and *An. darlingi* [49, 56]). An *Anopheles* species-specific serological platform could advance vector surveillance by more accurately capturing exposure to DVS in the South American and Asia Pacific regions which exhibit diverse biting behaviours and vector competence (DVS typically bite outdoors during the night and day respectively [19, 57-61]), as well as the increasing threat of urban malaria from *An. stephensi* in Africa [62, 63].

317 Importantly, this review demonstrated that the prevalence of *Anopheles* salivary antibodies increased 318 with increasing prevalence of *Plasmodium* spp. infection as well as established epidemiological 319 measures of malaria transmission: malaria endemicity class and EIR. Anti-salivary antibodies, such as 320 SG6 IgG, therefore, have the potential to serve as a proxy measure for vectorial capacity and malaria 321 receptivity of a population to sustain malaria transmission. Their application could be particularly 322 relevant in pre-elimination areas, or non-endemic areas under threat of imported malaria, where 323 Anopheles salivary antibodies are more readily detectable than parasites; salivary antibodies were 324 predicted to be prevalent (20%) in areas defined as eliminating malaria (<1% PfPR₂₋₁₀). Furthermore, if 325 SG6 IgG seroprevalence can be effectively combined with a measurement of the sporozoite index, 326 salivary antibodies as a marker of HBR could help overcome sensitivity limitations of EIR in low transmission areas. Additional measures could include estimates of malaria prevalence or serological 327 328 biomarkers that are species- or life stage-specific (e.g. *Plasmodium* spp. pre-erythrocytic antigens as 329 biomarkers for recent parasite inoculation). Indeed, positive associations between antibodies specific for *Plasmodium* spp. pre-erythrocytic and blood-stage antigens with gSG6 were demonstrated in 330 331 analyses of data from diverse malaria endemic areas. Serological tools combining salivary antigens with 332 antigens specific for the different *Plasmodium* spp. would be particularly beneficial in the Asia Pacific, 333 a region of relatively low malaria transmission with goals of elimination, but the highest burden of P. 334 vivax malaria where blood-stage infection can be caused by relapses from dormant liver stages. In these 335 areas, parasite prevalence may therefore overestimate ongoing malaria transmission, making vector 336 surveillance tools essential to informing elimination strategies in the Asia Pacific and other regions 337 where *P. vivax* is endemic.

338 The gold standard entomological measures HBR and EIR provide crude population-level estimates of 339 vector and malaria exposure that are specific in space and time and preclude investigation of individual-340 level heterogeneity and natural transmission dynamics. Our study demonstrated that salivary 341 biomarkers measured at the individual-level, such as gSG6 IgG, can be used to quantify total vector 342 exposure at the population-level, without requiring laborious entomological experiments. However, 343 validating an individual-level serological measure, which demonstrates considerable individual-level 344 variation, against the imperfect population-level gold standards of HBR and EIR is challenging and 345 reflected in the variation in study-specific estimates in the association between gSG6 IgG and HBR in modelling analyses. However, the accuracy of salivary antibodies to measure individual-level exposure 346 347 to Anopheles bites is yet to be validated; literature searches identified no studies investigating this 348 association at the individual-level. Without detailed measurements of individual-level vector exposure, 349 or a detailed knowledge of the half-life of Anopheles salivary antibodies post biting event, the true 350 accuracy of salivary antibodies, such as SG6 IgG, to measure individual-level HBR remains unknown. 351 This knowledge is particularly pertinent where *Anopheles* salivary biomarkers might be applied to 352 assess the effectiveness of a vector control intervention or used to measure temporal changes in malaria 353 transmission; particularly in areas or populations where there is considerable heterogeneity in 354 individual-level risk of Anopheles exposure (e.g. unmeasured outdoor biting due to occupational 355 exposure for forest workers [64]).

The broad nature of our inclusion and quality criteria was a key strength of our systematic review, which 356 aimed to provide a comprehensive analysis of all Anopheles salivary biomarkers and determine their 357 358 associations with entomological and malariometric measures of transmission. However, this review has 359 two main limitations. First, despite the inclusive nature, assessment of the external validity of the review 360 revealed a moderate risk of bias; some studies exhibited a high risk of selection bias as they were 361 performed in specific high-risk populations not representative of the overall population (*i.e.* children only). This is accounted for to some degree by specification of a random effect (*i.e.* intercept) for study, 362 363 which accounts for unmeasured study-specific factors that may introduce study-specific measurement 364 error to measurement of the outcome. Second, with respect to internal validity, there may be potential

365 selection bias introduced by the exclusion of studies reporting zero HBR (seven observations from three 366 studies [9, 36, 53]), EIR (22 observations from three studies [9, 13, 29]) and malaria prevalence (15 367 observations from three studies [15, 36, 51]) estimates, given we modelled the log of these factors. However, adding a small constant (e.g. 0.001) to a zero value to permit modelling of a log estimate can 368 369 also introduce considerable bias (*i.e.* seemingly small differences between values become very large on 370 the log scale). In light of this, we also chose to provide estimates of association and gSG6 IgG 371 seroprevalence according to widely accepted, discrete, endemicity classes (which permitted inclusion of all studies) and according to a selected range of epidemiologically relevant hypothetical HBR's (no 372 373 widely accepted HBR classification exists in the literature) to provide epidemiological context.

374 Conclusions

375 In order to advance progress towards malaria elimination the World Health Organisation has called for 376 innovative tools and improved approaches to enhance vector surveillance and monitoring and 377 evaluation of interventions [65]. Our systematic review has provided strong evidence that Anopheles 378 salivary antibodies are serological biomarkers of vector and malaria exposure, by quantifying their 379 strong positive association with Anopheles-HBR and established epidemiological measures of malaria 380 transmission. These salivary biomarkers have the potential to replace crude population-level 381 entomological experiments with a precise and scalable tool that measures Anopheles vector exposure at 382 the individual-level. This approach could be expanded into a sero-surveillance tool to assess the 383 effectiveness of vector control interventions, define heterogeneity in malaria transmission and inform 384 efficient resource-allocation, that would ultimately accelerate progress towards elimination.

385 **Contributors**

All authors developed the protocol and the analytical plan. EAK performed literature searches, screened studies and extracted data with input from FJIF. EAK and PAA analysed the data. All authors interpreted the data. EAK and FJIF drafted the report. All authors read and critically revised the draft report, and approved the final report. All authors agreed to be accountable for all aspects of the work.

Declaration of interests

391 We declare no competing interests.

392 Acknowledgements

393 We wish to thank the authors of the original studies for responding to requests for further 394 information/data for inclusion in the systematic review.

395 This work was supported by the National Health and Medical Research Council of Australia (Australian 396 Centre for Research Excellence in Malaria Elimination (ACREME) to FJIF and JAS (1134989); Career 397 Development Fellowship to FJIF (1166753) and investigator award to JAS (1196068); and its 398 Independent Research Institute Infrastructure Support Scheme), the Australian Commonwealth 399 Government (Australian Government Research Training Program Scholarship awarded to EK) and a 400 Victorian State Government Operational Infrastructure Support Program received by the Burnet 401 Institute. This research was funded in part by the Wellcome Trust (220211). For the purpose of Open 402 Access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript 403 version arising from this submission. The funders had no role in the study design, data collection or analysis, decision to publish, or preparation of the manuscript. 404

medRxiv preprint doi: https://doi.org/10.1101/2021.09.14.21263589; this version posted September 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

References 405

406 Monroe A, Moore S, Okumu F, Kiware S, Lobo NF, Koenker H, Sherrard-Smith E, Gimnig J, Killeen 1. 407 GF. Methods and indicators for measuring patterns of human exposure to malaria vectors. Malar J. 408 2020;19(1):207. doi: 10.1186/s12936-020-03271-z.

409 Mathenge EM, Misiani GO, Oulo DO, Irungu LW, Ndegwa PN, Smith TA, Killeen GF, Knols BGJ. 2. 410 Comparative performance of the Mbita trap, CDC light trap and the human landing catch in the sampling of 411 Anopheles arabiensis, An. funestus and culicine species in a rice irrigation in western Kenya. Malar J. 2005;4. 412 doi: 10.1186/1475-2875-4-7. PubMed PMID: 15667666.

413 Badu K, Siangla J, Larbi J, Lawson BW, Afrane Y, Ong'echa J, Remoue F, Zhou G, Githeko AK, Yan 3. 414 G. Variation in exposure to Anopheles gambiae salivary gland peptide (gSG6-P1) across different malaria 415 transmission settings in the western Kenya highlands. Malar J. 2012;11:318. doi: 10.1186/1475-2875-11-318.

416 Drame PM, Diallo A, Poinsignon A, Boussari O, Dos Santos S, Machault V, Lalou R, Cornelie S, 4. 417 LeHesran JY, Remoue F. Evaluation of the effectiveness of malaria vector control measures in urban settings of 418 Dakar by a specific Anopheles salivary biomarker. PLoS One. 2013;8(6):e66354. doi: 419 10.1371/journal.pone.0066354.

420 Drame PM, Poinsignon A, Besnard P, Cornelie S, Le Mire J, Toto JC, Foumane V, Dos-Santos MA, 5. Sembène M, Fortes F, Simondon F, Carnevale P, Remoue F. Human antibody responses to the Anopheles salivary 421 gSG6-P1 peptide: a novel tool for evaluating the efficacy of ITNs in malaria vector control. PLoS One. 422 423 2010;5(12):e15596. doi: 10.1371/journal.pone.0015596.

424 Drame PM, Poinsignon A, Besnard P, Le Mire J, Dos-Santos MA, Sow CS, Cornelie S, Foumane V, 6. 425 Toto JC, Sembene M, Boulanger D, Simondon F, Fortes F, Carnevale P, Remoue F. Human antibody response to 426 Anopheles gambiae saliva: an immuno-epidemiological biomarker to evaluate the efficacy of insecticide-treated 427 nets in malaria vector control. Am J Trop Med Hyg. 2010;83(1):115-21. doi: 10.4269/ajtmh.2010.09-0684.

428 7. Drame PM, Poinsignon A, Dechavanne C, Cottrell G, Farce M, Ladekpo R, Massougbodji A, Cornélie 429 S, Courtin D, Migot-Nabias F, Garcia A, Remoué F. Specific antibodies to Anopheles gSG6-P1 salivary peptide 430 to assess early childhood exposure to malaria vector bites. Malar J. 2015;14:285. doi: 10.1186/s12936-015-0800-431 6.

432 Rizzo C, Ronca R, Fiorentino G, Mangano VD, Sirima SB, Nèbiè I, Petrarca V, Modiano D, Arcà B. 8. 433 Wide cross-reactivity between Anopheles gambiae and Anopheles funestus SG6 salivary proteins supports 434 exploitation of gSG6 as a marker of human exposure to major malaria vectors in tropical Africa. Malar J. 435 2011;10:206. doi: 10.1186/1475-2875-10-206.

436 Rizzo C, Ronca R, Fiorentino G, Verra F, Mangano V, Poinsignon A, Sirima SB, Nèbiè I, Lombardo F, 9. 437 Remoue F, Coluzzi M, Petrarca V, Modiano D, Arcà B. Humoral response to the Anopheles gambiae salivary 438 protein gSG6: a serological indicator of exposure to Afrotropical malaria vectors. PLoS One. 2011;6(3):e17980. 439 doi: 10.1371/journal.pone.0017980.

440 10. Stone W, Bousema T, Jones S, Gesase S, Hashim R, Gosling R, Carneiro I, Chandramohan D, Theander 441 T, Ronca R, Modiano D, Arcà B, Drakeley C. IgG responses to Anopheles gambiae salivary antigen gSG6 detect variation in exposure to malaria vectors and disease risk. PLoS One. 2012;7(6):e40170. doi: 442 443 10.1371/journal.pone.0040170.

444 11. Drame PM, Machault V, Diallo A, Cornélie S, Poinsignon A, Lalou R, Sembène M, Dos Santos S, Rogier 445 C, Pagès F, Le Hesran JY, Remoué F. IgG responses to the gSG6-P1 salivary peptide for evaluating human 446 exposure to Anopheles bites in urban areas of Dakar region, Sénégal. Malar J. 2012;11:72. doi: 10.1186/1475-447 2875-11-72.

448 Londono-Renteria B, Drame PM, Weitzel T, Rosas R, Gripping C, Cardenas JC, Alvares M, Wesson 12. 449 DM, Poinsignon A, Remoue F, Colpitts TM. An. gambiae gSG6-P1 evaluation as a proxy for human-vector 450 contact in the Americas: a pilot study. Parasit Vectors. 2015;8:533. doi: 10.1186/s13071-015-1160-3.

451 Ya-Umphan P, Cerqueira D, Parker DM, Cottrell G, Poinsignon A, Remoue F, Brengues C, 13. 452 Chareonviriyaphap T, Nosten F, Corbel V. Use of an Anopheles salivary biomarker to assess malaria transmission 453 risk along the Thailand-Myanmar Border. J Infect Dis. 2017;215(3):396-404. doi: 10.1093/infdis/jiw543.

454 Noukpo MH, Damien GB, Elanga-N'Dille E, Sagna AB, Drame PM, Chaffa E, Boussari O, Corbel V, 14. 455 Akogbéto M, Remoue F. Operational assessment of long-lasting insecticidal nets by using an Anopheles salivary 456

biomarker of human-vector contact. Am J Trop Med Hyg. 2016;95(6):1376-82. doi: 10.4269/ajtmh.15-0541.

457 Idris ZM, Chan CW, Mohammed M, Kalkoa M, Taleo G, Junker K, Arcà B, Drakeley C, Kaneko A. 15. 458 Serological measures to assess the efficacy of malaria control programme on Ambae Island, Vanuatu. Parasit

459 Vectors. 2017;10(1):204. doi: 10.1186/s13071-017-2139-z.

perpetuity. It is made available under a CC-BY 4.0 International license .

460 16. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred Reporting Items for Systematic Reviews
461 and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097. doi:
462 10.1371/journal.pmed.1000097.

463 17. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA,
464 Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of
465 Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-12. Epub 2000/05/02. doi:
466 10.1001/jama.283.15.2008. PubMed PMID: 10789670.

467 18. Yamba EI, Tompkins AM, Fink AH, Ermert V, Djouda A, Amekudzi LK, Briët OJT. Monthly 468 entomological inoculation rates for studying malaria transmission seasonality in Africa. PANGAEA; 2018.

469 19. The Malaria Atlas Project [Internet]. 2017. Available from: https://malariaatlas.org/.

Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle K, Moyes CL, Henry A,
Eckhoff PA, Wenger EA, Briët O, Penny MA, Smith TA, Bennett A, Yukich J, Eisele TP, Griffin JT, Fergus CA,
Lynch M, Lindgren F, Cohen JM, Murray CLJ, Smith DL, Hay SI, Cibulskis RE, Gething PW. The effect of
malaria control on *Plasmodium falciparum* in Africa between 2000 and 2015. Nature. 2015;526(7572):207-11.
Epub 2015/09/16. doi: 10.1038/nature15535. PubMed PMID: 26375008.

Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, Rudan I. Global, regional, and national
prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis.
Lancet Glob Health. 2019;7(8):e1020-e30. doi: 10.1016/S2214-109X(19)30255-4.

478 22. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R. Assessing risk
479 of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin
480 Epidemiol. 2012;65(9):934-9. doi: 10.1016/j.jclinepi.2011.11.014.

Lawaly R, Konate L, Marrama L, Dia I, Diallo D, Sarr FD, Schneider BS, Casademont I, Diallo M, Brey
PT, Sakuntabhai A, Mecheri S, Paul R. Impact of mosquito bites on asexual parasite density and gametocyte
prevalence in asymptomatic chronic *Plasmodium falciparum* infections and correlation with IgE and IgG titers.
Infect Immun. 2012;80(6):2240-6. doi: 10.1128/iai.06414-11. PubMed PMID: WOS:000304387700031.

485 24. Rizzo C, Lombardo F, Ronca R, Mangano V, Sirima SB, Nèbiè I, Fiorentino G, Modiano D, Arcà B.
486 Differential antibody response to the *Anopheles gambiae* gSG6 and cE5 salivary proteins in individuals naturally
487 exposed to bites of malaria vectors. Parasit Vectors. 2014;7:549. doi: 10.1186/s13071-014-0549-8.

Rizzo C, Ronca R, Lombardo F, Mangano V, Sirima SB, Nèbiè I, Fiorentino G, Troye-Blomberg M,
Modiano D, Arcà B. IgG1 and IgG4 antibody responses to the *Anopheles gambiae* salivary protein gSG6 in the
sympatric ethnic groups Mossi and Fulani in a malaria hyperhendemic area of Burkina Faso. PLoS One.
2014;9(4):e96130. doi: 10.1371/journal.pone.0096130.

492 26. Waitayakul A, Somsri S, Sattabongkot J, Looareesuwan S, Cui L, Udomsangpetch R. Natural human
493 humoral response to salivary gland proteins of *Anopheles* mosquitoes in Thailand. Acta Trop. 2006;98(1):66-73.
494 doi: 10.1016/j.actatropica.2006.02.004.

495 27. Brosseau L, Drame PM, Besnard P, Toto JC, Foumane V, Le Mire J, Mouchet F, Remoue F, Allan R,
496 Fortes F, Carnevale P, Manguin S. Human antibody response to *Anopheles* saliva for comparing the efficacy of
497 three malaria vector control methods in Balombo, Angola. PLoS One. 2012;7(9):e44189. doi:
498 10.1371/journal.pone.0044189.

Marie A, Ronca R, Poinsignon A, Lombardo F, Drame PM, Cornelie S, Besnard P, Le Mire J, Fiorentino
G, Fortes F, Carnevale P, Remoue F, Arcà B. The *Anopheles gambiae* cE5 salivary protein: a sensitive biomarker
to evaluate the efficacy of insecticide-treated nets in malaria vector control. Microbes Infect. 2015;17(6):409-16.
doi: 10.1016/j.micinf.2015.01.002.

Soma DD, Kassié D, Sanou S, Karama FB, Ouari A, Mamai W, Ouédraogo GA, Salem G, Dabiré RK,
Fournet F. Uneven malaria transmission in geographically distinct districts of Bobo-Dioulasso, Burkina Faso.
Parasit Vectors. 2018;11(1):296. doi: 10.1186/s13071-018-2857-x.

S06 30. Koffi D, Touré AO, Varela ML, Vigan-Womas I, Béourou S, Brou S, Ehouman MF, Gnamien L, Richard
V, Djaman JA, Perraut R. Analysis of antibody profiles in symptomatic malaria in three sentinel sites of Ivory
Coast by using multiplex, fluorescent, magnetic, bead-based serological assay (MAGPIX[™]). Malar J.
2015;14:509. doi: 10.1186/s12936-015-1043-2.

510 31. Koffi D, Varela ML, Loucoubar C, Beourou S, Vigan-Womas I, Touré A, Djaman JA, Touré AO, Perraut
511 R. Longitudinal analysis of antibody responses in symptomatic malaria cases do not mirror parasite transmission
512 in peri-urban area of Cote d'Ivoire between 2010 and 2013. PLoS One. 2017;12(2):e0172899. doi:
513 10.1371/journal.pone.0172899.

514 32. Traoré DF, Sagna AB, Adja AM, Zoh DD, Lingué KN, Coulibaly I, N'Cho Tchiekoi B, Assi SB,

Poinsignon A, Dagnogo M, Remoue F. Evaluation of malaria urban risk using an immuno-epidemiological
biomarker of human exposure to *Anopheles* bites. Am J Trop Med Hyg. 2018;98(5):1353-9. doi:
10.4269/ajtmh.17-0231.

Traoré DF, Sagna AB, Adja AM, Zoh DD, Adou KA, Lingué KN, Coulibaly I, Tchiekoi NB, Assi SB,
 Poinsignon A, Dagnogo M, Remoue F. Exploring the heterogeneity of human exposure to malaria vectors in an

perpetuity. It is made available under a CC-BY 4.0 International license .

urban setting, Bouaké, Côte d'Ivoire, using an immuno-epidemiological biomarker. Malar J. 2019;18(1):68. doi:
10.1186/s12936-019-2696-z.

Sadia-Kacou CAM, Yobo CM, Adja MA, Sagna AB, Ndille EE, Poinsignon A, Tano Y, Koudou BG,
Remoue F. Use of *Anopheles* salivary biomarker to assess seasonal variation of human exposure to *Anopheles*bites in children living near rubber and oil palm cultivations in Côte d'Ivoire. Parasite Epidemiol Control.
2019;5:e00102. doi: 10.1016/j.parepi.2019.e00102.

35. Badu K, Gyan B, Appawu M, Mensah D, Dodoo D, Yan G, Drakeley C, Zhou G, Owusu-Dabo E, Koram
KA. Serological evidence of vector and parasite exposure in Southern Ghana: the dynamics of malaria
transmission intensity. Parasit Vectors. 2015;8:251. doi: 10.1186/s13071-015-0861-y.

Sagna AB, Sarr JB, Gaayeb L, Drame PM, Ndiath MO, Senghor S, Sow CS, Poinsignon A, Seck M,
Hermann E, Schacht A-M, Faye N, Sokhna C, Remoue F, Riveau G. gSG6-P1 salivary biomarker discriminates
micro-geographical heterogeneity of human exposure to *Anopheles* bites in low and seasonal malaria areas. Parasit
Vectors. 2013;6(1):68. doi: 10.1186/1756-3305-6-68.

37. Poinsignon A, Samb B, Doucoure S, Drame PM, Sarr JB, Sow C, Cornelie S, Maiga S, Thiam C, Rogerie
F, Guindo S, Hermann E, Simondon F, Dia I, Riveau G, Konate L, Remoue F. First attempt to validate the gSG6P1 salivary peptide as an immuno-epidemiological tool for evaluating human exposure to *Anopheles funestus*bites. Trop Med Int Health. 2010;15(10):1198-203. doi: 10.1111/j.1365-3156.2010.02611.x.

Sarr JB, Samb B, Sagna AB, Fortin S, Doucoure S, Sow C, Senghor S, Gaayeb L, Guindo S, Schacht
AM, Rogerie F, Hermann E, Dia I, Konate L, Riveau G, Remoue F. Differential acquisition of human antibody
responses to *Plasmodium falciparum* according to intensity of exposure to *Anopheles* bites. Trans R Soc Trop
Med Hyg. 2012;106(8):460-7. doi: 10.1016/j.trstmh.2012.05.006.

Ali ZM, Bakli M, Fontaine A, Bakkali N, Vu Hai V, Audebert S, Boublik Y, Pagès F, Remoué F, Rogier
C, Fraisier C, Almeras L. Assessment of *Anopheles* salivary antigens as individual exposure biomarkers to
species-specific malaria vector bites. Malar J. 2012;11:439. doi: 10.1186/1475-2875-11-439.

Ambrosino E, Dumoulin C, Orlandi-Pradines E, Remoue F, Toure-Baldé A, Tall A, Sarr JB, Poinsignon
A, Sokhna C, Puget K, Trape JF, Pascual A, Druilhe P, Fusai T, Rogier C. A multiplex assay for the simultaneous
detection of antibodies against 15 *Plasmodium falciparum* and *Anopheles gambiae* saliva antigens. Malar J.
2010;9:317. doi: 10.1186/1475-2875-9-317.

41. Perraut R, Varela ML, Loucoubar C, Niass O, Sidibé A, Tall A, Trape JF, Wotodjo AN, Mbengue B,
Sokhna C, Vigan-Womas I, Touré A, Richard V, Mercereau-Puijalon O. Serological signatures of declining
exposure following intensification of integrated malaria control in two rural Senegalese communities. PLoS One.
2017;12(6):e0179146. doi: 10.1371/journal.pone.0179146.

552 42. Poinsignon A, Cornelie S, Mestres-Simon M, Lanfrancotti A, Rossignol M, Boulanger D, Cisse B, 553 Sokhna C, Arcà B, Simondon F, Remoue F. Novel peptide marker corresponding to salivary protein gSG6 554 potentially identifies exposure Anopheles bites. PLoS 2008;3(6):e2472. to One. doi: 555 10.1371/journal.pone.0002472.

43. Poinsignon A, Cornelie S, Ba F, Boulanger D, Sow C, Rossignol M, Sokhna C, Cisse B, Simondon F,
Remoue F. Human IgG response to a salivary peptide, gSG6-PI, as a new immuno-epidemiological tool for
evaluating low-level exposure to *Anopheles* bites. Malar J. 2009;8. doi: 10.1186/1475-2875-8-198. PubMed
PMID: WOS:000269875000001.

Kemoue F, Cisse B, Ba F, Sokhna C, Herve JP, Boulanger D, Simondon F. Evaluation of the antibody
response to *Anopheles* salivary antigens as a potential marker of risk of malaria. Trans R Soc Trop Med Hyg.
2006;100(4):363-70. doi: 10.1016/j.trstmh.2005.06.032.

Sagna AB, Kassié D, Couvray A, Adja AM, Hermann E, Riveau G, Salem G, Fournet F, Remoue F.
Spatial assessment of contact between humans and *Anopheles* and *Aedes* mosquitoes in a medium-sized African urban setting, using salivary antibody-based biomarkers. J Infect Dis. 2019;220(7):1199-208. doi: 10.1093/infdis/jiz289.

567 46. Yman V, White MT, Rono J, Arca B, Osier FH, Troye-Blomberg M, Bostrom S, Ronca R, Rooth I,
568 Farnert A. Antibody acquisition models: A new tool for serological surveillance of malaria transmission intensity.
569 Sci Rep. 2016;6. doi: 10.1038/srep19472. PubMed PMID: WOS:000369380100001.

47. Proietti C, Verra F, Bretscher MT, Stone W, Kanoi BN, Balikagala B, Egwang TG, Corran P, Ronca R,
571 Arcà B, Riley EM, Crisanti A, Drakeley C, Bousema T. Influence of infection on malaria-specific antibody
572 dynamics in a cohort exposed to intense malaria transmission in northern Uganda. Parasite Immunol. 2013;35(5573 6):164-73. doi: 10.1111/pim.12031.

48. Andrade BB, Rocha BC, Reis-Filho A, Camargo LM, Tadei WP, Moreira LA, Barral A, Barral-Netto
M. Anti-*Anopheles darlingi* saliva antibodies as marker of *Plasmodium vivax* infection and clinical immunity in
the Brazilian Amazon. Malar J. 2009;8:121. doi: 10.1186/1475-2875-8-121.

49. Londono-Renteria B, Drame PM, Montiel J, Vasquez AM, Tobón-Castaño A, Taylor M, Vizcaino L,
578 Lenhart AAE. Identification and pilot evaluation of salivary peptides from *Anopheles albimanus* as biomarkers
579 for bite exposure and malaria infection in Colombia. Int J Mol Sci. 2020;21(3). doi: 10.3390/ijms21030691.

perpetuity. It is made available under a CC-BY 4.0 International license .

580 50. Montiel J, Carbal LF, Tobón-Castaño A, Vásquez GM, Fisher ML, Londono-Rentería B. IgG antibody
581 response against *Anopheles* salivary gland proteins in asymptomatic *Plasmodium* infections in Narino, Colombia.
582 Malar J. 2020;19(1):42. doi: 10.1186/s12936-020-3128-9.

583 51. Kerkhof K, Sluydts V, Willen L, Kim S, Canier L, Heng S, Tsuboi T, Sochantha T, Sovannaroth S,
584 Ménard D, Coosemans M, Durnez L. Serological markers to measure recent changes in malaria at population
585 level in Cambodia. Malar J. 2016;15(1):1-18. doi: 10.1186/s12936-016-1576-z.

586 52. Charlwood JD, Hall T, Nenhep S, Rippon E, Branca-Lopes A, Steen K, Arca B, Drakeley C. Spatial
587 repellents and malaria transmission in an endemic area of Cambodia with high mosquito net usage. MalariaWorld
588 J. 2017;8(11).

589 53. Pollard EJM, Patterson C, Russell TL, Apairamo A, Oscar J, Arcà B, Drakeley C, Burkot TR. Human 590 exposure to *Anopheles farauti* bites in the Solomon Islands is not associated with IgG antibody response to the 591 gSG6 salivary protein of *Anopheles gambiae*. Malar J. 2019;18(1):334. doi: 10.1186/s12936-019-2975-8.

592 54. *Plasmodium falciparum* Paratsite Rate 2-10 year olds [Internet]. MAP. 2020. Available from: 593 https://malariaatlas.org/.

594 55. Arcà B, Lombardo F, Struchiner CJ, Ribeiro JM. Anopheline salivary protein genes and gene families:
595 an evolutionary overview after the whole genome sequence of sixteen *Anopheles* species. BMC Genomics.
596 2017;18(1):153. doi: 10.1186/s12864-017-3579-8.

597 56. Londono-Renteria B, Montiel J, Calvo E, Tobón-Castaño A, Valdivia HO, Escobedo-Vargas K, Romero
598 L, Bosantes M, Fisher ML, Conway MJ, Vásquez GM, Lenhart AE. Antibody responses against *Anopheles*599 *darlingi* immunogenic peptides in *Plasmodium* infected humans. Front Cell Infect Microbiol. 2020;10(455). doi:
600 10.3389/fcimb.2020.00455.

57. Trung HD, Bortel WV, Sochantha T, Keokenchanh K, Briët OJ, Coosemans M. Behavioural
 heterogeneity of Anopheles species in ecologically different localities in Southeast Asia: a challenge for vector
 control. Trop Med Int Health. 2005;10(3):251-62.

58. Sinka ME, Bangs MJ, Manguin S, Rubio-Palis Y, Chareonviriyaphap T, Coetzee M, Mbogo CM,
Hemingway J, Patil AP, Temperley WH. A global map of dominant malaria vectors. Parasit Vectors.
2012;5(1):69.

59. Sinka ME, Rubio-Palis Y, Manguin S, Patil AP, Temperley WH, Gething PW, Van Boeckel T, Kabaria
608 CW, Harbach RE, Hay SI. The dominant *Anopheles* vectors of human malaria in the Americas: occurrence data,
609 distribution maps and bionomic précis. Parasit Vectors. 2010;3(1):72. doi: 10.1186/1756-3305-3-72.

610 60. Herrera S, Ochoa-Orozco SA, González IJ, Peinado L, Quiñones ML, Arévalo-Herrera M. Prospects for
611 malaria elimination in Mesoamerica and Hispaniola. PLoS Negl Trop Dis. 2015;9(5):e0003700. Epub 2015/05/15.
612 doi: 10.1371/journal.pntd.0003700. PubMed PMID: 25973753; PubMed Central PMCID: PMCPMC4431857.

613 61. Chaumeau V, Fustec B, Nay Hsel S, Montazeau C, Naw Nyo S, Metaane S, Sawasdichai S,
 614 Kittiphanakun P, Phatharakokordbun P, Kwansomboon N, Andolina C, Cerqueira D, Chareonviriyaphap T,
 615 Nosten FH, Corbel V. Entomological determinants of malaria transmission in Kayin state, Eastern Myanmar: A
 616 24-month longitudinal study in four villages. Wellcome Open Res. 2018;3:109. Epub 2019/06/27. doi:

617 10.12688/wellcomeopenres.14761.4. PubMed PMID: 31206035; PubMed Central PMCID: PMCPMC6544137.

618 62. Takken W, Lindsay S. Increased threat of urban malaria from *Anopheles stephensi* mosquitoes, Africa.
619 Emerg Infect Dis. 2019;25(7):1431-3. Epub 2019/07/17. doi: 10.3201/eid2507.190301. PubMed PMID: 31063455.

63. Sinka ME, Pironon S, Massey NC, Longbottom J, Hemingway J, Moyes CL, Willis KJ. A new malaria
vector in Africa: Predicting the expansion range of *Anopheles stephensi* and identifying the urban populations at
risk. Proc Natl Acad Sci USA. 2020;117(40):24900. doi: 10.1073/pnas.2003976117.

624 64. Sandfort M, Vantaux A, Kim S, Obadia T, Pepey A, Gardais S, Khim N, Lek D, White M, Robinson LJ,
625 Witkowski B, Mueller I. Forest malaria in Cambodia: the occupational and spatial clustering of *Plasmodium vivax*626 and *Plasmodium falciparum* infection risk in a cross-sectional survey in Mondulkiri province, Cambodia. Malar
627 J. 2020;19(1):413. doi: 10.1186/s12936-020-03482-4.

628 65. World Health Organization. Global vector control response 2017–2030. Geneva: WHO, 2017.

629 Supplementary Files

| 630 | Supplementary File 1. Supplementary Methodology |
|-----|--|
| 631 | Supplementary File 2. Risk of Bias assessment |
| 632 | Figure 1 - Supplement 1. Reasons for study exclusion |
| 633 | Figure 2 – Supplement 1: Association between gSG6 IgG seropositivity and human biting rate38 |
| 634 | Figure 3 – Supplement 1: Association between gSG6 IgG seropositivity and entomological inoculation |
| 635 | rate |
| 636 | Figure 4 – Supplement 1: Association between gSG6 IgG seropositivity and Human Biting Rate |
| 637 | (HBR), moderated by dominant vector species |
| 638 | Figure 5 – Supplement 1. Association between gSG6 IgG seropositivity and malaria prevalence41 |
| 639 | Supplementary File 3. Association between gSG6 IgG seropositivity and antimalarial antibody |
| 640 | seroprevalence |
| 641 | Antibodies against <i>P. falciparum</i> pre-erythrocytic stage antigens |
| 642 | Antibodies against <i>P. falciparum</i> blood stage antigens |
| 643 | Antibodies against <i>P. vivax</i> antigens |
| 644 | Supplementary File 4. Country and study-specific predicted probability of gSG6 IgG seropositivity. |
| 645 | |
| 646 | Supplementary File 5. Association between alternative salivary biomarkers and exposures of interest. |
| 647 | |
| 648 | Human biting rate |
| 649 | Entomological inoculation rate |
| 650 | Malaria prevalence |
| 651 | Antimalarial antibody seroprevalence |
| 652 | Supplementary References |

653 Supplementary File 1. Supplementary Methodology.

654 Search strategy

We performed a systematic review with multilevel modelling of the published literature according to the Metaanalysis of Observational Studies in Epidemiology (MOOSE) guidelines [1] and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) specifications [2]. The protocol was registered with PROSPERO (CRD42020185449).

659 The electronic databases PubMed, Scopus, Web of Science, African Index Medicus, and the Latin American and 660 Caribbean Health Sciences Literature (LILACS) were searched for studies published before June 30, 2020 661 investigating Anopheles salivary antigens as a biomarker for mosquito exposure or malaria transmission. Search 662 terms were as follows: Anophel* AND saliva* AND (antibod* OR sero* OR antigen OR marker* OR biomarker* 663 OR gSG6* OR gSG* OR SG* OR cE5). The reference lists of included studies were screened for additional 664 studies, and Google Scholar was used to identify additional works by key authors. No formal attempt was made 665 to identify unpublished population studies as it would have required significant description of the design, methods 666 and analysis used in these studies, and a review of ethical issues.

667 Selection criteria

668 The primary criteria for inclusion in this systematic review was the reporting of estimates of seroprevalence or 669 total levels of Immunoglobulin (Ig) antibodies (including all isotypes and subclasses) in human sera against 670 recombinant or synthetic peptide Anopheles salivary antigens. We considered for inclusion: cross-sectional 671 studies, cohort studies, intervention studies and case-control studies of individuals or populations (including sub-672 populations) living in all geographies with natural exposure to Anopheles mosquitoes. Studies that were solely 673 performed in participants not representative of the wider population (i.e. mosquito allergic patients, soldiers, 674 returned travellers) were excluded. The minimum quality criteria for inclusion in this review were: antibody 675 detection performed using enzyme-linked immunosorbent assay (ELISA), multiplex or Luminex assays.

The exposure variables of interest included entomological and malariometric parameters, including: (i) human biting rate (HBR), defined as the number of bites received per person per unit of time; (ii) entomological inoculation rate (EIR), defined as the number of infectious bites per person per unit of time, calculated as the HBR multiplied by the sporozoite index; (iii) estimates of malaria prevalence; (iv) population-level seroprevalence estimates against *Plasmodium* spp. malarial antigens. To ensure HBR estimates were given for the same unit of time (bites per person per night), biting rates given per week were divided by 7, and biting rates given per month

682 we multiplied by 12 and divided by 365. Similar approaches were employed to ensure consistent units for EIR 683 (infectious bites per person per year). *Plasmodium* spp. infections had to be confirmed by either microscopy, rapid 684 diagnostic test (RDT) or molecular methods (polymerase chain reaction (PCR)). Plasmodium spp. diagnosis was 685 included for all *Plasmodium* spp. combined and the species-level if provided. Where exposure estimates were not 686 provided, we attempted to source data from other publications by the authors, or using the site geolocation and 687 year to obtain estimates of EIR from the Pangaea dataset [3]. P. falciparum rates in 2-10 year olds (globally, 688 2000–2017) and dominant vector species (DVS) from the Malaria Atlas Project (MAP) [4]. Studies of salivary 689 antigens where exposure variables could not be sourced and data that could not be extracted were excluded.

690 Selection of studies

691 One author performed database searches and screened reference lists to identify possible studies. One author 692 screened studies against inclusion criteria, with discussion and input from a second reviewer.

693 Approaches to include all available studies

694 The authors of any studies that did not contain relevant information on the study design, populations, eligibility 695 criteria, or key study data, were contacted and relevant data requested. Authors were contacted via an initial email 696 detailing the precise nature of the systematic review and the data required. If the authors did not reply to three 697 email requests, or were unable to provide relevant data, the studies were deemed to insufficiently meet 698 inclusion/quality criteria and were excluded. As measurement of antibody levels does not produce a common 699 metric between studies, authors were asked to classify their participants as 'responders' or 'no-responders' 700 according to seropositivity (antibody level relative to unexposed sera) within each study, to allow comparisons of 701 seroprevalence between studies [5-7]. Studies that were only able to provide antibody levels or categorised 702 seropositivity based upon arbitrary cut offs were excluded from multilevel modelling analyses and included in 703 narrative terms. Where the salivary antibody response and exposure variable were measured in the same 704 population and reported in multiple publications, the study with the largest sample size was included, otherwise 705 the earliest study was included.

706 Data extraction

Data were extracted using a data collection form by one reviewer. Any data that was provided at the subpopulation level was extracted at the lowest level i.e. if a study was performed across multiple sites, and an estimate for both salivary antibody seroprevalence/levels and the outcome of interest is given for each site, it was included the site level, rather than an aggregated level.

711 Measures

712 Outcomes

The primary outcome of interest of our systematic review was the reported antibody response (both seroprevalence and levels of all Ig subclasses and isotypes) to *Anopheles* salivary antigens. Multilevel modelling analyses were performed where the seroprevalence of antibodies against the same antigen and the exposure of interest were reported in more than one study.

717 *Exposures*

The primary exposures of interest included in the multilevel modelling analyses were the HBR and EIR, a measure of the average number of bites received per person per night and infectious bites received per person per year, respectively. Secondary exposures assessed include the prevalence of any *Plasmodium* spp. infection (including *P. falciparum* only, *P. vivax* only, or untyped infections). Additional secondary exposures include the *P. falciparum* infection rate in 2-10 year olds extracted from MAP, as well as the seroprevalence of antimalarial antibodies against pre-erythrocytic and blood-stage antigens.

Clinical and methodological heterogeneity were explored using prespecified variables to minimize spurious findings. Variables considered for inclusion were study design (cohort, cross-sectional, repeated cross-sectional), DVS, study participants (adults only, children only, adults and children), preparation of salivary antigen (recombinant full-length protein, synthetic peptide), malaria detection methodology (light microscopy, RDT, PCR), and entomological vector collection methodology (human landing catch, light traps, and spray catches).

729 Statistical analysis

730 Where there were sufficient data to pool estimates of the same exposure and outcome measures, generalised linear 731 mixed modelling (GLMM) was used to undertake analyses quantifying associations between the exposures of 732 interest and salivary antibody seroprevalence measurements. Models were generalised through use of the logit 733 link function and binomial distribution (statistical notation for HBR model shown below as equation one). 734 Seroprevalence was modelled in binomial form as the number of individuals seropositive to the total sample size. 735 A three-level random effects model with a nested framework was used to account for dependency in the data, with 736 random intercepts for country (level-3) and study (level-2) and level-1 units representing multiple observations 737 per study induced by the study design (*i.e.* multiple time points, sites, age categories). Additionally, random slopes 738 for entomological and malariometric exposure parameters were included to permit the effect of the exposure of 739 interest (HBR/EIR/malaria prevalence/etc.) to vary across studies. Model structure was determined empirically

740 through likelihood ratio tests (p < 0.05), with the exception of country at the 3rd level which was included in HBR 741 and EIR analyses to estimate country-specific seroprevalence estimates of anti-salivary antibodies. The 742 associations between the various exposures and the different salivary antigens were analysed separately, however 743 estimates of IgG seroprevalence against the recombinant full-length protein (gSG6) and synthetic peptide (gSG6-744 P1, the one peptide determined in all studies utilising peptides) form of the gSG6 antigen were analysed together, 745 with a fixed term for antigen construct considered for inclusion in the model. Of note, gSG6 peptide 2 (gSG6-P2) 746 was excluded from being analysed with gSG6 and gSG6-P1 estimates, as the two studies that reported anti-gSG6-747 P2 IgG seroprevalence also reported the seroprevalence of anti-gSG6-P1 IgG, and only one could be included. 748 Potential effect modification of the associations between the exposures of interest and the anti-Anopheles salivary 749 antibody responses was explored was undertaken by estimating interaction terms for DVS (An. gambiae sensu 750 lato (s.l.) only, An. gambiae s.l. and other DVS, or An. gambiae s.l. absent) and for vector collection method 751 (human landing catch or other indirect measures e.g. light traps, spray catches, etc.). For the association between 752 *Plasmodium* spp. prevalence and gSG6 IgG seropositivity interaction terms for malaria detection methodology 753 (light microscopy or PCR), and malarial species type (P. falciparum only, or P. falciparum and P. vivax) were 754 estimated. Other variables considered for inclusion in adjusted models were study design, participant, salivary 755 antigen construct; however, these variables showed no association with anti-gSG6 IgG and were thus excluded.

The natural log of HBR, EIR, malaria prevalence and antimalarial antibody seroprevalence were modelled to account for the non-linear functional form of the association between each measure and the log odds of anti-gSG6 IgG seroprevalence - supported empirically by superior model fit as indicated by Akaike's information criterion (AIC) and Bayesian information criterion (BIC) fit indices. To aid interpretation, odds ratios are presented according to relative per cent increase in the exposures, such that odds ratios reflect relative changes in anti-gSG6 IgG seropositivity for 50% increases HBR and EIR, and 10% increases in malaria prevalence and antimalarial seroprevalence. Additional per cent changes in HBR and EIR are also presented.

Empirical Bayes best linear unbiased predictions (BLUPs) were used to estimate the probability of gSG6 IgG seropositivity in the average study and country, which is equivalent to an estimated gSG6 IgG seroprevalence. In order to maximise the number of included studies in our modelling, we predicted anti-gSG6 seroprevalence according to endemicity class, derived by applying established endemicity cut-offs to *Pf*PR₂₋₁₀ estimates [8] extracted from MAP using site year and geolocation (if MAP data unavailable endemicity as stated in study). Intraclass correlation coefficients (ICCs) and 95% reference ranges were estimated for country-, study- and slopespecific heterogeneity (where appropriate) using estimated model variance components.

770 Statistical notation for the generalised linear mixed model used to estimate the association between

- 771 Anopheles gambiae gSG6 IgG seropositivity and human biting rate (HBR).
- The model can be formally written as:

773
$$\log it\{\Pr(y_{ij}=1) \mid x_{ij}, \zeta_{1j}, \zeta_{2i}, \zeta_{3j} \log(HBR)_{ij}\} = \beta_1 + \beta_2 \log(HBR)_{ij} + \zeta_{1j} + \zeta_{2i} + \zeta_{3i} \log(HBR)_{ij}, \quad (1)$$

774 where

775
$$\zeta_{1j} \sim N(0,\psi_1), \ \zeta_{2i} \sim N(0,\psi_2) \text{ and } \zeta_{3j} \log(HBR)_{ij} \sim N(0,\psi_3),$$
 (2)

776

Where x_{ij} is the vector of model covariates, β_1 is the model constant and represents the log odds (probability) of gSG6 IgG seropositivity for a log HBR of zero, β_2 the fixed effect for log HBR for country *j* and study *i*, ζ_{1j} the random-effect (i.e. intercept) for between-country heterogeneity in probability of gSG6 IgG seropositivity, ζ_{2i} , the random-effect (i.e. intercept) for between-study heterogeneity in probability of gSG6 IgG seropositivity, and ζ_{3i} the random-effect (i.e. coefficient) for between-study heterogeneity in the effect of log HBR.

782

783 Risk of bias in individual studies

For cross-sectional, cohort or intervention studies, selection bias was assessed by reviewing the studies' inclusion and exclusion criteria. Any case-control studies, or studies that presented salivary antibody data stratified by malaria infection status were included in narrative terms only. Risk of bias was assessed by one reviewer using the Risk of Bias in Prevalence Studies tool [9]. The risk of bias pertains to the reported seroprevalence estimates of anti-*Anopheles* salivary antibodies included in the multilevel modelling.

789 Supplementary File 2. Risk of Bias assessment.

790 Risk of bias was assessed for each study by one independent reviewer using the Risk of Bias in Prevalence Studies 791 tool [9]. This tool comprises 10 items and a summary assessment to assess the external validity (selection and 792 non-response bias) and internal validity (measurement bias) of the study's prevalence estimates. The risk of bias 793 pertains to the reported seroprevalence estimates of anti-Anopheles salivary antibodies included in the multilevel 794 modelling. 795 With regard to external validity, seven of the studies included in the review were performed in specific populations 796 (*i.e.* children only) that were not representative of the national population and were deemed to be at high risk of 797 selection bias. Only 7 studies included some form of random sampling, and frequently insufficient detail was

provided on the sampling frame; as such most studies were included as high risk of selection bias. Furthermore,

no studies reported participant response-rate, and as such were indicated as high risk of nonresponse bias.

800 In terms of internal validity, all studies had an acceptable case definition, with the same mode of data collection,

801 a valid instrument and an acceptable prevalence period, so were all deemed to be of low risk. However, 12 studies

did not include a denominator, instead only reporting the study sample size and prevalence estimate, and wereincluded as high risk.

Overall, due to the specific nature of some of the sample populations for which these prevalence estimates are given (*i.e.* children only) and as participant non-response rate is not given, we conclude that there is a moderate risk of study bias. According to the *Risk of Bias in Prevalence Studies* tool [9], this implies that future research is

807 likely to have an impact on our confidence in the prevalence estimates.




Figure 1 - Supplement 1. Reasons for study exclusion.

Table S1: Reasons for study exclusion

| Studies | Reason | References |
|---------|--|------------|
| 30 | Does not measure anti-salivary antibody responses in individuals/populations | [10-39] |
| 28 | Review article | [40-67] |
| 20 | Anopheles salivary antigens not assessed | [68-87] |
| 10 | Wrong antibody detection methodologies | [88-97] |
| 7 | Grey literature | [98-104] |
| 6 | Not performed in humans | [105-110] |
| 4 | Data already captured by our review from another publication | [111-114] |
| 3 | Unable to determine appropriate exposure estimate | [115-117] |
| 3 | Not in population with natural exposure | [118-120] |
| 1 | Hypothesis study | [121] |
| 1 | Pooled sera | [122] |
| 1 | Does not provide estimate of seroprevalence/total levels of antibodies against salivary proteins | [123] |
| 1 | Study population not representative: Mosquito allergic patients | [124] |
| 1 | Study population not representative: Soldiers with transient exposure | [125] |

814 Figure 2 – Supplement 1: Association between gSG6 IgG seropositivity and human biting rate

815

816 Table S1: Unadjusted association between gSG6 IgG seropositivity and log Human Biting Rate (HBR).

| Variable | Log Odds Ratio (SE) | 95% CI | p-value | RE |
|--------------------|---------------------|------------|---------|---------|
| Fixed part | | | | |
| log HBR | 0.29 (0.08) | 0.14, 0.45 | < 0.001 | |
| Random part | | | | |
| $\psi_1{}^{\circ}$ | | | | 1.29 |
| ψ_2 | | | | 1.55 |
| ψ_3 | | | | 0.06 |
| $ ho_1{}^d$ | | | | 0.21 |
| $\rho_2^{\rm e}$ | | | | 0.47 |
| l | | | | -1489.9 |
| Model fit indices | | | | |
| AIC | | | | 2989.9 |
| BIC | | | | 3004.2 |

817 Human biting rate (HBR) association: log odds ratio and standard error (SE), 95% confidence interval (95%CI),

818 p-value, random-effect components (RE): variances (ψ), conditional intraclass correlation coefficient (ρ)^a and

819 model log likelihood (ℓ) from generalised multilevel modelling.^b This analysis is based upon n=132 meta-820 observations.

821 a $\rho = \frac{\psi_k + ... + \psi_{nk}}{\psi_k + ... + \psi_{nk} + \pi^2/3}$, where ψ_k through ψ_{nk} are random-effect variance estimates pertaining to each of the 822 respective variance components (see table notes ^{c-e}) from the generalised multilevel modelling for a specific ICC 823 estimate.

^b Generalised multilevel modelling estimating the association between log transformed HBR and anti-gSG6 IgG
 seropositivity with random-effects for country-specific and study-specific heterogeneity in gSG6 IgG
 seroprevalence and study-specific heterogeneity in effect of HBR.

827 ${}^{c}\psi_{1}, \psi_{2}$ and ψ_{3} represent variances of the random-effects for country, study and effect of HBR respectively.

828 ${}^{d}\rho_{1}$ represents conditional ICC for meta-observations from the same country but different study.

829 $^{\rm e}\rho_2$ represents conditional ICC for meta-observations from the same country and study with the median HBR

830 Figure 3 – Supplement 1: Association between gSG6 IgG seropositivity and entomological

- 831 inoculation rate
- 832

Table S1: Unadjusted association between gSG6 IgG seropositivity log Entomological Inoculation Rate 833 834 (EIR).

| Variable | Log Odds Ratio (SE) | 95% CI | p-value | RE |
|-------------------|---------------------|------------|---------|--------|
| Fixed part | | | | |
| log EIR | 0.15 (0.04) | 0.07, 0.23 | < 0.001 | |
| Random part | | | | |
| $\psi_1{}^{ m c}$ | | | | 1.02 |
| ψ_2 | | | | 2.15 |
| ψ_3 | | | | 0.01 |
| $ ho_1{}^d$ | | | | 0.16 |
| ρ_2^{e} | | | | 0.49 |
| l | | | | -530.7 |
| Model fit indices | | | | |
| AIC | | | | 1071.3 |
| BIC | | | | 1079.5 |

Entomological inoculation rate (EIR) association: log odds ratio and standard error (SE), 95% confidence interval 835

836 (95% CI), p-value, random-effect components (RE): variances (ψ), conditional intraclass correlation coefficient

837 $(\rho)^{a}$ and model log likelihood (ℓ) from generalised multilevel modelling.^b This analysis is based upon n=38 meta-

838 observations.

^a $\rho = \frac{\psi_k + ... + \psi_{nk}}{\psi_k + ... + \psi_{nk} + \pi^2/3}$, where ψ_k through ψ_{nk} are random-effect variance estimates pertaining to each of the 839 840 respective variance components (see table notes ^{c-e}) from the generalised multilevel modelling for a specific ICC

841 estimate.

842 ^b Generalised multilevel modelling estimating the association between log transformed EIR and anti-gSG6 IgG seropositivity with random-effects for country-specific and study-specific heterogeneity in gSG6 IgG 843 844 seroprevalence and study-specific heterogeneity in effect of EIR.

 ${}^{c}\psi_{1},\psi_{2}$ and ψ_{3} represent variances of the random-effects for country, study and effect of EIR respectively. 845

 ${}^{d}\rho_{1}$ represents the conditional ICC for meta-observations from the same country but different study . 846

847 ${}^{e}\rho_{2}$ represents the conditional ICC for meta-observations from the same country and study with the median EIR

848 Figure 4 – Supplement 1: Association between gSG6 IgG seropositivity and Human Biting Rate

849 (HBR), moderated by dominant vector species

850

Table S1: Association between gSG6 IgG seropositivity and log Human Biting Rate (HBR), moderated by 851 852 dominant vector species

| Variable | Log Odds Ratio (SE) | 95% CI | p-value | RE |
|------------------------------|---------------------|--------------|----------|---------|
| Fixed part | | | | |
| log HBR | 0.46 (0.11) | 0.25, 0.66 | < 0.001 | |
| DVS | | | < 0.001* | |
| An. gambiae s.l. only | Ref. | | | |
| An. gambiae s.l. & other DVS | 1.00 (0.18) | 0.65, 1.25 | < 0.001 | |
| Non-An. gambiae s.l. | 1.09 (0.68) | -0.24, 2.42 | 0.109 | |
| log HBR by DVS | | | < 0.001* | |
| An. gambiae s.l. only | Ref. | | | |
| An. gambiae s.l. & other DVS | -0.26 (0.08) | -0.41, -0.11 | 0.001 | |
| Non-An. gambiae s.l. | -0.38 (0.11) | -0.59, -0.17 | < 0.001 | |
| Random part | | | | |
| $\psi_1{}^c$ | | | | 0.96 |
| ψ_2 | | | | 2.32 |
| ψ_3 | | | | 0.08 |
| $ ho_1{}^d$ | | | | 0.14 |
| ρ_2^{e} | | | | 0.51 |
| l | | | | -1488.8 |
| Model fit indices | | | | |
| AIC | | | | 2995.53 |
| BIC | | | | 3021.48 |

853 Human biting rate (HBR) X dominant vector species (DVS) association: log odds ratio and standard error (SE), 854 95% confidence interval (95% CI), p-value, random-effect components (RE): variances (ψ), conditional intraclass correlation coefficient $(\rho)^a$ and model log likelihood (ℓ) from generalised multilevel modelling.^b *indicates p-855 value from joint Wald test for polytomous variables. This analysis is based upon n=132 meta-observations. 856

^a $\rho = \frac{\psi_k + ... + \psi_{nk}}{\psi_k + ... + \psi_{nk} + \pi^2/3}$, where ψ_k through ψ_{nk} are random-effect variance estimates pertaining to each of the 857 858 respective variance components (see table notes ^{c-e}) from the generalised multilevel modelling for a specific ICC

859 estimate. 860 ^b Generalised multilevel modelling estimating the association between log transformed HBR and anti-gSG6 IgG 861 seropositivity including an interaction term between DVS and log HBR with random-effects for country-specific 862 and study-specific heterogeneity in gSG6 IgG seroprevalence and study-specific heterogeneity in effect of HBR.

 ${}^{c}\psi_{1},\psi_{2}$ and ψ_{3} represent variances of the random-effects for country, study and effect of HBR respectively. 863

864 ${}^{d}\rho_{1}$ represents the conditional ICC for meta-observations from the same country but different study .

865 ${}^{\circ}\rho_{2}$ represents the conditional ICC for meta-observations from the same country and study with the median HBR

866 Figure 5 – Supplement 1. Association between gSG6 IgG seropositivity and malaria prevalence

867

868 Table S1: Unadjusted association between gSG6 IgG seropositivity and log *Plasmodium* spp. prevalence.

| Variable | Log Odds Ratio (SE) | 95% CI | p-value | RE |
|--------------------------------|---------------------|-------------|---------|---------|
| Fixed part | | | | |
| log Plasmodium spp. prevalence | 0.46 (0.32) | -0.16, 1.08 | 0.148 | |
| Random part | | | | |
| $\psi_1{}^{ m c}$ | | | | 17.21 |
| ψ_2 | | | | 1.25 |
| $ ho_1{}^{ m d}$ | | | | 0.85 |
| l | | | | -2597.2 |
| Model fit indices | | | | |
| AIC | | | | 5202.47 |
| BIC | | | | 5215.90 |

869 Any *Plasmodium* species infections (including prevalence estimates of *P. falciparum* only, *P. vivax* only, both *P.*

falciparum and *P. vivax* and un-typed infections): log odds ratio and standard error (SE), 95% confidence interval

871 (95%CI), p-value, random-effect components (RE): variances (ψ), conditional intraclass correlation coefficient 872 (ρ)^a and model log likelihood (ℓ) from generalised multilevel modelling.^b This analysis is based upon n=212

873 meta-observations.

874 a $\rho = \frac{\psi_k + ... + \psi_{nk}}{\psi_k + ... + \psi_{nk} + \pi^2/3}$, where ψ_k through ψ_{nk} are random-effect variance estimates pertaining to each of the 875 respective variance components (see table notes ^{c-d}) from the generalised multilevel modelling for a specific ICC 876 estimate.

b Generalised multilevel modelling estimating the association between the log prevalence of any *Plasmodium* spp.
 infection and anti-gSG6 IgG seropositivity with random-effects for study-specific heterogeneity in gSG6 IgG
 seroprevalence and study-specific heterogeneity in effect of *Plasmodium* spp. prevalence.

880 ${}^{c}\psi_{1}$ and ψ_{2} represent variances of the random-effects for study and effect of *Plasmodium* spp. prevalence 881 respectively.

 $^{d}\rho_{1}$ represents the conditional ICC for meta-observations from the same study and with the median *Plasmodium* spp. prevalence.

884 Supplementary File 3. Association between gSG6 IgG seropositivity and antimalarial antibody

885 seroprevalence

886 Antibodies against *P. falciparum* pre-erythrocytic stage antigens

- 887 The pooled analysis of 159 meta-observations from eight studies showed that a 10% relative increase in PfCSP
- 888 IgG seropositivity was associated with a 11% (OR: 1.11; 95% CI: 1.02-1.21%, p=0.013) increase in odds of anti-
- 889 gSG6 IgG seropositivity [126-133]. Furthermore we observed that gSG6 IgG levels increased with increasing
- 890 PfCSP IgG seroprevalence in four studies [127-129, 133], with another study contributing only a single estimate
- 891 [132].
- 892 Antibodies against *P. falciparum* blood stage antigens
- 893 Furthermore, we observed a 10% relative increase PfAMA1 IgG seroprevalence was associated with a 13% (OR: 894 1.13; 95% CI: 1.12-1.15%; p<0.001) increase in odds of gSG6 IgG seropositivity, based upon 62 meta-895 observations from eight studies [128-135]. A similar association was observed for PfMSP1₁₉ IgG, with 10% 896 relative increase in seroprevalence associated with 13% (OR: 1.13; 95%CI: 1.03-1.25%; p=0.014) increase in 897 odds of gSG6 IgG seropositivity. This association was derived from 163 meta-observations from ten studies [127-898 130, 132-136]. Analysis of 47 meta-observations from three studies indicated that a 10% relative increase in 899 PfMSP2 IgG seroprevalence was associated with a 5% (OR: 1.05; 95% CI: 1.03-1.07%; p<0.001) increase in odds 900 of gSG6 IgG seropositivity [130, 133, 135]. While 17 meta-observations from two studies showed a 10% relative 901 increase in PfMSP3 IgG seroprevalence was associated with a 14% (OR: 1.14; 95%CI: 1.13-1.16%; p<0.001) 902 increase in odds of gSG6 IgG seropositivity [132, 135].
- The pooled analysis of 128 meta-observations from five studies showed that a 10% relative increase in PfGLURP IgG seroprevalence was associated with a 17% (OR: 1.17; 95%CI: 1.14-1.19%; p<0.001) increase in odds of gSG6 IgG seropositivity [126-130]. And 18 meta-observations from five studies indicated that 10% relative increase in *P. falciparum* schizont extract IgG seropositivity was associated with a 27% (OR: 1.27; 95%CI: 0.61-
- 907 2.65%; *p*=0.523) increase in odds of gSG6 IgG seropositivity [128-130, 134, 137].
- 908 We observed that increasing seroprevalence of IgG antibodies against PfAMA1 saw increased levels of anti-gSG6
- 909 IgG in three studies [128, 129, 134], but no association in another [133]. The levels of gSG6 IgG increased with
- 910 increasing PfMSP1₁₉ IgG seroprevalence in three studies [128, 134, 136], but showed no association in three other
- 911 studies [127, 129, 133]. No association between gSG6 IgG levels and MSP2 IgG seroprevalence was observed in
- 912 one study [133]. PfGLURP IgG seroprevalence and gSG6 IgG antibody levels were reported in three studies,

- 913 with one study reporting increased levels [128], one study reporting no association [127], and one study reporting
- 914 decreased levels of anti-gSG6 IgG with increasing anti-PfGLURP seroprevalence [129]. One study showed
- 915 increasing gSG6 IgG levels with increasing *P. falciparum* schizont extract IgG, while three other studies showed
- 916 no association [128, 129, 137]. Of note, one study provided a single seroprevalence estimate of antibodies against
- 917 PfAMA1, PfMSP1₁₉ and PfMSP3 so no relationships can be drawn [132].
- 918 Antibodies against *P. vivax* antigens
- 919 In pooled analyses of 115 meta-observations from two studies [127, 134], we observed that 10% relative increase
- 920 in the seroprevalence of PvAMA1 was associated with a 20% (OR: 1.20; 95%CI: 1.19-1.22%; p<0.001) increase
- 921 in the odds of anti-gSG6 IgG seropositivity. Furthermore, in 103 meta-observations from two studies [127, 134],
- 922 10% relative increase in PvMSP1₁₉ IgG seroprevalence was associated with a 13% (OR: 1.13; 95%CI: 1.12-
- 923 1.13%; p<0.001) increase in the odds of anti-gSG6 IgG seropositivity. However, neither study showed an
- association between the levels of gSG6 IgG and the seroprevalence of PvAMA1 and PvMSP1₁₉ IgG [127, 134].

925 Table S1: Associations between anti-gSG6 IgG seropositivity and log of antimalarial antibody seroprevalence.

| Exposure | Log Odds Ratio (SE) | 95%CI | p- value | Meta-N | Studies | References |
|---|---------------------|--------------|----------|--------|---------|---------------------|
| Pre-erythrocytic antigens | | | | | | |
| log PfCSP IgG Seroprevalence (%) | 1.13 (0.45) | 0.24, 2.01 | 0.013 | 159 | 8 | [126-133] |
| Blood stage antigens | | | | | | |
| log PfAMA1 IgG Seroprevalence (%) ^a | 1.30 (0.07) | 1.17, 1.44 | < 0.001 | 62 | 8 | [128-135] |
| log PfMSP119 IgG Seroprevalence (%) | 1.31 (0.53) | 0.27, 2.36 | 0.014 | 163 | 10 | [127-130, 132-136] |
| log PfMSP2 IgG Seroprevalence (%) | 0.50 (0.11) | 0.27, 0.72 | < 0.001 | 47 | 3 | [130, 133, 135] |
| log PfMSP3 IgG Seroprevalence (%) ^a | 1.41 (0.09) | 1.24, 1.58 | < 0.001 | 17 | 2 | [132, 135] |
| log PfGLURP IgG Seroprevalence (%) | 1.61 (0.12) | 1.37, 1.85 | < 0.001 | 128 | 5 | [126-130] |
| log PfSchizont Extract IgG Seroprevalence (%) | 2.51 (3.93) | -5.20, 10.22 | 0.523 | 18 | 5 | [128-130, 134, 137] |
| log PvAMA1 IgG Seroprevalence (%) | 1.95 (0.08) | 1.79, 2.11 | < 0.001 | 115 | 2 | [127, 134] |
| log PvMSP1 ₁₉ IgG Seroprevalence (%) | 1.25 (0.04) | 1.17, 1.32 | < 0.001 | 103 | 2 | [127, 134] |

926 Effects for each exposure represent separate generalised multilevel modelling analyses estimating the association between the log of the seroprevalence of antimalarial

927 antibodies and the seroprevalence of anti-gSG6 IgG, with the inclusion of a random intercept for study-specific heterogeneity and a random coefficient to allow the effect of

928 the antimalarial antigen to vary across studies. Table shows log odds ratio and standard error (SE), 95% confidence interval (95%CI) and p-value, number of meta-observations 929 (Meta-N) and studies, with associated references. Random effects not shown.

930 ^a Studies did not include a random coefficient (*i.e.* slope); as empirical support was not shown.

- 931 Supplementary File 4. Country and study-specific predicted probability of gSG6 IgG
- 932 seropositivity.
- 933 In order to obtain estimates of gSG6 IgG seroprevalence for each country and study, an intercept only three-level
- 934 random effects logistic regression was fitted to 301 meta-observations from 22 studies. The predicted probability
- 935 of gSG6 IgG seropositivity was calculated at the country-level (Figure S1), indicating that the seroprevalence was
- 936 lowest in the Pacific Region (Vanuatu (31%) and Solomon Islands (32%)) and highest in Benin (72%) and Burkina
- Faso (65%). Furthermore, the predicted probability of gSG6 IgG seropositivity was calculated at the study-level
- 938 (Figure S2) indicating that the seroprevalence was lowest in Ambrosino *et al.* [126] (13%) and highest in Drame *et*
- 939 *al.* [138] (91%).



940

941 Figure S1: Predicted gSG6 IgG seroprevalence by country. Predicted probabilities of gSG6 IgG seropositivity including country-specific random effects with 95% 942 confidence intervals. Estimated from intercept-only three-level random-effects logistic regression to account for the hierarchical nature of the data, with an anti-gSG6 IgG meta-943 observation nested within study nested within country. Based upon 301 meta-observations from 22 studies.



945 Figure S2: Predicted gSG6 IgG seroprevalence by study. Predicted probabilities of gSG6 IgG seropositivity including study-specific random effects with 95% confidence 946 intervals. Estimated from intercept-only three-level random-effects logistic regression to account for the hierarchical nature of the data, with an anti-gSG6 IgG meta-observation 947

947 nested within study nested within country. Based upon 301 meta-observations from 22 studies.

948 Supplementary File 5. Association between alternative salivary biomarkers and exposures of 949 interest.

950 Our systematic review identified a paucity of studies that assessed the relationship between our exposures of 951 interest and most alternate Anopheles salivary biomarkers (that is non-An. gambiae gSG6 IgG), thus preventing 952 the estimation of a pooled association. The exceptions being that we observed that a 50% relative increase in HBR 953 was associated with a 7% increase (OR: 1.07; 95%CI: 1.01-1.13%; p=0.017) in odds of anti-An. funestus fSG6 954 IgG seropositivity (six meta-observations from two studies [139, 140]; Table 1), as well as a 42% (OR: 1.42; 955 95% CI: 1.39-1.46%; p<0.001) and 21% (OR: 1.21; 95% CI: 1.19-1.23%; p<0.001) increase in odds of anti-gSG6-956 P2 IgG seropositivity associated with 10% relative increase in seroprevalence of PfCSP and PfGLURP IgG, 957 respectively (115 and 116 meta-observations from two studies respectively [126, 127], Table 2-3). The 958 associations between exposures of interest and the additional salivary biomarkers are further discussed in narrative 959 terms in below.

960 Human biting rate

961 In addition to the increased odds of An. funestus fSG6 seropositivity with increasing HBR, the majority of studies 962 reported a positive association between HBR and the seroprevalence and levels of anti-gSG6-P1 IgM [138], the 963 levels of gSG6-P2 IgG [141], the seroprevalence and levels of anti-cE5 IgG [142], the levels of anti-fSG6 IgG 964 [139, 140], the seroprevalence and levels of anti-f5'nuc IgG [139] and the median levels of anti-An. gambiae 965 salivary gland extracts (SGE) SGE IgG and IgG4 [143-145]. One study reported similar median levels of anti-966 gSG6 IgG1 across populations and time points, whilst reporting that anti-gSG6 IgG4 titre increased with 967 increasing HBR in one of the populations, but not in the other [146]. Similarly, there was no consistent association 968 between HBR and the levels of anti-CE5 IgG [147], levels of anti-An. gambiae SGE IgE [145] and the 969 seroprevalence and levels of anti-g5'nuc IgG [139].

970 **Entomological inoculation rate**

- 971 Ali et al. [139] reported higher seroprevalence and levels anti-fSG6 IgG and anti-f5'nuc IgG with increasing EIR,
- 972 while anti-g5'nuc IgG seroprevalence and levels were not associated with EIR. An additional study reported
- 973 gSG6-P2 IgG seroprevalence estimates of 0% for three sites, irrespective of EIR [126].

974 Malaria prevalence

975 Two studies showed that increased *Plasmodium* spp. prevalence was associated with higher median levels of anti-976 An. gambiae SGE IgG [143, 148], while another study showed different anti-An. gambiae SGE IgG levels for 977 very similar prevalence of malaria and slightly lower levels of anti-An. gambiae SGE IgE and IgG4 for the time 978 point with greater malaria prevalence [145]. Kerkhof et al. [127] showed increasing levels of anti-gSG6-P2 IgG 979 for higher prevalence of any *Plasmodium* spp. infection, while Londono-Renteria *et al.* [149] showed lower levels 980 of IgG antibodies against TRANS-P1, TRANS-P2, PEROX-P1, PEROX-P2 and PEROX-P3 in the site with 981 higher PCR confirmed malaria prevalence. Additionally, several case-controlled studies, and two cross-sectional 982 study, reported median antibody levels stratified by malaria infection status. These studies show higher levels of 983 anti-An. darlingi SGE IgG [150], anti-An. gambiae SGE IgG [144], anti-An. dirus SGE IgG and IgM [151], and 984 IgG antibodies against SGEs of two Colombian strains of An. albimanus in Plasmodium spp. infected individuals, 985 compared to non-infected [152]. While Montiel et al. [152] observed no association between anti-An. darlingi 986 SGE IgG levels and infection status.

987 Antimalarial antibody seroprevalence

988 Our multilevel modelling indicated that there were 42% (OR: 1.42; 95% CI: 1.39-1.46%; *p*<0.001) and 21% (OR:

989 1.21; 95%CI: 1.19-1.23%; p<0.001) increase in odds of anti-gSG6-P2 IgG seropositivity associated with a 10% 990 relative increase in the seroprevalence of PfCSP and PfGLURP IgG, respectively [126, 127]. However, we 991 observed weak positive associations between the levels of IgG antibodies against gSG6-P2 peptide and the 992 seroprevalence of IgG antibodies against PfMSP1₁₉, PfGLURP and PvMSP1₁₉, but no association with PfCSP or

993 PvAMA1 [127].

994 Table S1: Association between fSG6 IgG seropositivity and human biting rate

| Variable | Log Odds Ratio (SE) | 95% CI | p-value | RE |
|-------------------|---------------------|------------|---------|------|
| Fixed part | | | | |
| log HBR | 0.17 (0.07) | 0.03, 0.31 | 0.017 | |
| Random part | | | | |
| $\psi_1{}^{ m c}$ | | | | 0.47 |
| $ ho_1{}^{ m d}$ | | | | 0.13 |

995 Association between human biting rate (HBR) and fSG6 IgG: log odds ratio and standard error (SE), 95% 996 confidence interval (95% CI), p-value, random-effect components (RE): variances (ψ), conditional intraclass 997 correlation coefficient (ρ)^a and model log likelihood (ℓ) from generalised multilevel modelling.^b This analysis is 998 based upon n=6 meta-observations.

 $\frac{\psi_k + ... + \psi_{nk}}{\psi_k + ... + \psi_{nk} + \pi^2/3}$, where ψ_k through ψ_{nk} are random-effect variance estimates pertaining to each of the 999 1000 respective variance components (see table notes ^{c-d}) from the mixed-effect generalised (logit) linear mixed models 1001 for a specific ICC estimate.

1002 ^b Generalised multilevel modelling estimating the association between anti-An. funestus fSG6 IgG seropositivity

1003 and log transformed HBR with random-effects for study-specific heterogeneity in fSG6 IgG seropositivity.

1004 ${}^{c}\psi_{1}$ represents variance of the random-effect for study.

 ${}^{d}\rho_{1}$ represents conditional ICC for meta-observations from the same study. 1005

- 1006
- 1007
- 1008
- 1009 1010

1011 Table S2: Association between gSG6-P2 IgG seropositivity and log PfCSP IgG seroprevalence

| Variable | Log Odds Ratio (SE) | 95% CI | p-value | RE |
|------------------------------|---------------------|------------|---------|------|
| Fixed part | | | | |
| log PfCSP IgG Seroprevalence | 3.70 (0.12) | 3.45, 3.94 | < 0.001 | |
| Random part | | | | |
| $\psi_1{}^{ m c}$ | | | | 25.2 |
| $ ho_1{}^{ m d}$ | | | | 0.88 |
| | | 1. | 1 1 | |

1012 Association between log PfCSP seroprevalence and gSG6-P2 IgG: log odds ratio and standard error (SE), 95%

1013 confidence interval (95%CI), p-value, random-effect variances (ψ), conditional intraclass correlation coefficient $(\rho)^{a}$ and model log likelihood (ℓ) from generalised multilevel modelling.^b This analysis is based upon n=115 1014 1015 meta-observations.

^a $\rho = \frac{\psi_k + ... + \psi_{nk}}{\psi_k + ... + \psi_{nk} + \pi^2/3}$, where ψ_k through ψ_{nk} are random-effect (RE) variance estimates pertaining to each of the 1016

1017 respective variance components (see table notes ^{c-d}) from the mixed–effect generalised (logit) linear mixed models 1018 for a specific ICC estimate.

^b Generalised multilevel modelling estimating the association between log PfCSP seroprevalence and anti-gSG6-1019

1020 P2 IgG seropositivity with random-effects for study-specific heterogeneity in gSG6-P2 IgG seropositivity.

1021 ${}^{c}\psi_{1}$ represents variance of the random-effect for study.

 ${}^{d}\rho_{1}$ represents conditional ICC for meta-observations from the same study. 1022

1023

1024

1025 Table S3: Association between gSG6-P2 IgG seropositivity and log PfGLURP IgG seroprevalence

| Variable | Log Odds Ratio (SE) | 95% CI | p-value | RE |
|--------------------------------|---------------------|------------|---------|------|
| Fixed part | | | | |
| log PfGLURP IgG Seroprevalence | 2.01 (0.09) | 1.85, 2.18 | < 0.001 | |
| Random part | | | | |
| $\psi_1{}^c$ | | | | 24.3 |
| $ ho_1{}^{ m d}$ | | | | 0.88 |

1026 Association between log PfGLURP seroprevalence and gSG6-P2 IgG: log odds ratio and standard error (SE), 1027 95% confidence interval (95%CI), p-value, random-effect variances (ψ), conditional intraclass correlation 1028 coefficient $(\rho)^a$ and model log likelihood (ℓ) from generalised multilevel modelling.^b This analysis is based upon 1029 n=116 meta-observations.

^a $\rho = \frac{\psi_k + ... + \psi_{nk}}{\psi_k + ... + \psi_{nk} + \pi^2/3}$, where ψ_k through ψ_{nk} are random-effect (RE) variance estimates pertaining to each of the 1030

1031 respective variance components (see table notes ^{c-d}) from the mixed-effect generalised (logit) linear mixed models 1032 for a specific ICC estimate.

^b Generalised multilevel modelling estimating the association between log PfGLURP seroprevalence and anti-1033

1034 gSG6-P2 IgG seropositivity with random-effects for study-specific heterogeneity in gSG6-P2 IgG seropositivity.

1035 ${}^{c}\psi_{1}$ represents variance of the random-effect for study.

 ${}^{d}\rho_{1}$ represents conditional ICC for meta-observations from the same study. 1036

medRxiv preprint doi: https://doi.org/10.1101/2021.09.14.21263589; this version posted September 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

1037 **Supplementary References**

1038 Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, 1. 1039 Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of 1040 Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-12. Epub 2000/05/02. doi: 1041 10.1001/jama.283.15.2008. PubMed PMID: 10789670.

1042 Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred Reporting Items for Systematic Reviews 2. 1043 and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097. doi: 1044 10.1371/journal.pmed.1000097.

1045 3. Yamba EI, Tompkins AM, Fink AH, Ermert V, Djouda A, Amekudzi LK, Briët OJT. Monthly 1046 entomological inoculation rates for studying malaria transmission seasonality in Africa. PANGAEA; 2018. 1047

The Malaria Atlas Project [Internet]. 2017. Available from: https://malariaatlas.org/. 4.

1048 5. Cutts JC, Agius PA, Zaw L, Powell R, Moore K, Draper B, Simpson JA, Fowkes FJI. Pregnancy-specific 1049 malarial immunity and risk of malaria in pregnancy and adverse birth outcomes: a systematic review. BMC Med. 1050 2020;18(1):14. Epub 2020/01/17. doi: 10.1186/s12916-019-1467-6. PubMed PMID: 31941488; PubMed Central 1051 PMCID: PMCPMC6964062.

1052 Cutts JC, Powell R, Agius PA, Beeson JG, Simpson JA, Fowkes FJ. Immunological markers of 6. 1053 Plasmodium vivax exposure and immunity: a systematic review and meta-analysis. BMC Med. 2014;12:150. Epub 1054 2014/09/10. doi: 10.1186/s12916-014-0150-1. PubMed PMID: 25199532; PubMed Central PMCID: 1055 PMCPMC4172944.

1056 7. Fowkes FJI, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies 1057 and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med. 1058 2010;7(1):e1000218-e. doi: 10.1371/journal.pmed.1000218. PubMed PMID: 20098724.

1059 8. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle K, Moyes CL, Henry A, 1060 Eckhoff PA, Wenger EA, Briët O, Penny MA, Smith TA, Bennett A, Yukich J, Eisele TP, Griffin JT, Fergus CA, 1061 Lynch M, Lindgren F, Cohen JM, Murray CLJ, Smith DL, Hay SI, Cibulskis RE, Gething PW. The effect of 1062 malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526(7572):207-11. 1063 Epub 2015/09/16. doi: 10.1038/nature15535. PubMed PMID: 26375008.

1064 9. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R. Assessing risk 1065 of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin 1066 Epidemiol. 2012;65(9):934-9. doi: 10.1016/j.jclinepi.2011.11.014.

Alvarenga PH, Francischetti IMB, Calvo E, Sa-Nunes A, Ribeiro JMC, Andersen JF. The Function and 1067 10. 1068 Three-Dimensional Structure of a Thromboxane A(2)/Cysteinyl Leukotriene-Binding Protein from the Saliva of 1069 a Mosquito Vector of the Malaria Parasite. PLoS Biol. 2010;8(11). doi: 10.1371/journal.pbio.1000547. PubMed 1070 PMID: WOS:000284762300019.

1071 11. Arcà B, Lombardo F, Struchiner CJ, Ribeiro JM. Anopheline salivary protein genes and gene families: 1072 an evolutionary overview after the whole genome sequence of sixteen Anopheles species. BMC Genomics. 1073 2017;18(1):153. doi: 10.1186/s12864-017-3579-8.

1074 Arcà B, Lombardo F, Valenzuela JG, Francischetti IMB, Marinotti O, Coluzzi M, Ribeiro JMC. An 12. 1075 updated catalogue of salivary gland transcripts in the adult female mosquito, Anopheles gambiae. J Exp Biol. 1076 2005;208(20):3971-86. doi: 10.1242/jeb.01849.

1077 Calvo E, Dao A, Pham VM, Ribeiro JM. An insight into the sialome of Anopheles funestus reveals an 13. 1078 emerging pattern in anopheline salivary protein families. Insect Biochem Mol Biol. 2007;37(2):164-75. doi: 1079 10.1016/j.ibmb.2006.11.005.

1080 Calvo E, Mans BJ, Andersen JF, Ribeiro JMC. Function and evolution of a mosquito salivary protein 14. 1081 family. J Biol Chem. 2006;281(4):1935-42. doi: 10.1074/jbc.M510359200.

1082 Choumet V, Carmi-Leroy A, Laurent C, Lenormand P, Rousselle JC, Namane A, Roth C, Brey PT. The 15. 1083 salivary glands and saliva of Anopheles gambiae as an essential step in the Plasmodium life cycle: A global 1084 proteomic study. Proteomics. 2007;7(18):3384-94. doi: 10.1002/pmic.200700334.

1085 16. Das S, Radtke A, Choi Y, Mendes AM, Valenzuela JG, Dimopoulos G. Transcriptomic and functional 1086 analysis of the Anopheles gambiae salivary gland in relation to blood feeding. BMC Genomics. 2010;11(1). doi: 1087 10.1186/1471-2164-11-566.

1088 Di Gaetano S, Del Gatto A, Pirone L, Comegna D, Zaccaro L, Saviano M, Arca B, Capasso D, Pedone 17. 1089 E. A selective alpha(v)beta(5) integrin antagonist hidden into the anophelin family protein cE5 from the malaria 1090 vector Anopheles gambiae. Peptide Science. 2018;110(5). doi: 10.1002/pep2.24054. PubMed PMID: 1091 WOS:000450664700016.

medRxiv preprint doi: https://doi.org/10.1101/2021.09.14.21263589; this version posted September 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

1092 18. Dixit R, Sharma A, Mourya DT, Kamaraju R, Patole MS, Shouche YS. Salivary gland transcriptome 1093 analysis during Plasmodium infection in malaria vector Anopheles stephensi. Int J Infect Dis. 2009;13(5):636-46. 1094 doi: 10.1016/j.ijid.2008.07.027.

1095 19. Francischetti IM, Ma D, Andersen JF, Ribeiro JM. Evidence for a lectin specific for sulfated glycans in 1096 the salivary gland of the malaria vector, Anopheles gambiae. PLoS One. 2014;9(9):e107295. doi: 1097 10.1371/journal.pone.0107295.

1098 Francischetti IM, Valenzuela JG, Pham VM, Garfield MK, Ribeiro JM. Toward a catalog for the 20. 1099 transcripts and proteins (sialome) from the salivary gland of the malaria vector Anopheles gambiae. J Exp Biol. 1100 2002;205(Pt 16):2429-51.

1101 Ghosh AK, Devenport M, Jethwaney D, Kalume DE, Pandey A, Anderson VE, Sultan AA, Kumar N, 21. 1102 Jacobs-Lorena M. Malaria parasite invasion of the mosquito salivary gland requires interaction between the 1103 Plasmodium TRAP and the Anopheles saglin proteins. PLoS Pathog. 2009;5(1):e1000265. doi: 1104 10.1371/journal.ppat.1000265.

1105 Isaacs AT, Mawejje HD, Tomlinson S, Rigden DJ, Donnelly MJ. Genome-wide transcriptional analyses 22 1106 in Anopheles mosquitoes reveal an unexpected association between salivary gland gene expression and insecticide 1107 resistance. BMC Genomics. 2018;19(1). doi: 10.1186/s12864-018-4605-1.

1108 23 Jariyapan N, Baimai V, Poovorawan Y, Roytrakul S, Saeung A, Thongsahuan S, Suwannamit S, Otsuka 1109 Y, Choochote W. Analysis of female salivary gland proteins of the Anopheles barbirostris complex (Diptera: 1110 Culicidae) in Thailand. Parasitol Res. 2010;107(3):509-16. doi: 10.1007/s00436-010-1883-1.

1111 Jariyapan N, Choochote W, Jitpakdi A, Harnnoi T, Siriyasatein P, Wilkinson MC, Bates PA. A glycine-24. 1112 and glutamate-rich protein is female salivary gland-specific and abundant in the malaria vector Anopheles dirus

1113 Entomol. 10.1603/0022-В (Diptera: Culicidae). J Med 2006;43(5):867-74. doi: 1114 2585(2006)43[867:AGAGPI]2.0.CO;2.

1115 25. Jariyapan N, Roytrakul S, Paemanee A, Junkum A, Saeung A, Thongsahuan S, Sor-suwan S, 1116 Phattanawiboon B, Poovorawan Y, Choochote W. Proteomic analysis of salivary glands of female Anopheles 1117 barbirostris species A2 (Diptera: Culicidae) by two-dimensional gel electrophoresis and mass spectrometry. 1118 Parasitol Res. 2012;111(3):1239-49. doi: 10.1007/s00436-012-2958-y.

1119

Kamiya T, Greischar MA, Mideo N. Epidemiological consequences of immune sensitisation by pre-26. 1120 exposure to vector saliva. PLoS Negl Trop Dis. 2017;11(10). doi: 10.1371/journal.pntd.0005956.

1121 Khaireh BA, Briolant S, Pascual A, Mokrane M, MacHault V, Travaillé C, Khaireh MA, Farah IH, Ali 27. 1122 HM, Abdi AIA, Ayeh SN, Darar HY, Ollivier L, Waiss MK, Bogreau H, Rogier C, Pradines B. Plasmodium vivax 1123 and Plasmodium falciparum infections in the Republic of Djibouti: Evaluation of their prevalence and potential 1124 determinants. Malar J. 2012;11. doi: 10.1186/1475-2875-11-395.

1125 Korochkina S, Barreau C, Pradel G, Jeffery E, Li J, Natarajan R, Shabanowitz J, Hunt D, Frevert U, 28. 1126 Vernick KD. A mosquito-specific protein family includes candidate receptors for malaria sporozoite invasion of 1127 salivary glands. Cell Microbiol. 2006;8(1):163-75. doi: 10.1111/j.1462-5822.2005.00611.x.

1128 Lombardo F, Ronca R, Rizzo C, Mestres-Simòn M, Lanfrancotti A, Currà C, Fiorentino G, Bourgouin 29 1129 C, Ribeiro JM, Petrarca V, Ponzi M, Coluzzi M, Arcà B. The Anopheles gambiae salivary protein gSG6: an 1130 anopheline-specific protein with a blood-feeding role. Insect Biochem Mol Biol. 2009;39(7):457-66. doi: 1131 10.1016/j.ibmb.2009.04.006.

1132 Pandey RK, Bhatt TK, Prajapati VK. Novel Immunoinformatics Approaches to Design Multi-epitope 30. Subunit Vaccine for Malaria by Investigating Anopheles Salivary Protein. Sci Rep. 2018;8(1):1125. doi: 1133 1134 10.1038/s41598-018-19456-1.

1135 31. Pedro PM, Sallum MAM. Spatial expansion and population structure of the neotropical malaria vector, 1136 Anopheles darlingi (Diptera: Culicidae). Biol J Linn Soc. 2009;97(4):854-66. doi: 10.1111/j.1095-1137 8312.2009.01226.x.

1138 Phattanawiboon B, Jariyapan N, Mano C, Roytrakul S, Paemanee A, Sor-Suwan S, Sriwichai P, Saeung 32. 1139 A, Bates PA. Salivary Gland Proteome during Adult Development and after Blood Feeding of Female Anopheles 1140 dissidens Mosquitoes (Diptera: Culicidae). PLoS One. 11(9):e0163810. doi: 10.1371/journal.pone.0163810.

1141 Pirone L, Ripoll-Rozada J, Leone M, Ronca R, Lombardo F, Fiorentino G, Andersen JF, Pereira PJB, 33.

1142 Arcà B, Pedone E. Functional analyses yield detailed insight into the mechanism of thrombin inhibition by the 1143 antihemostatic salivary protein cE5 from Anopheles gambiae. J Biol Chem. 2017;292(30):12632-42. doi: 1144 10.1074/jbc.M117.788042. PubMed PMID: PDB/3U69PDB/4E05PDB/5NHU.

1145 Rawal R, Vijay S, Kadian K, Singh J, Pande V, Sharma A. Towards a Proteomic Catalogue and 34. 1146 Differential Annotation of Salivary Gland Proteins in Blood Fed Malaria Vector Anopheles culicifacies by Mass 1147 Spectrometry. PLoS One. 2016;11(9):e0161870. doi: 10.1371/journal.pone.0161870.

medRxiv preprint doi: https://doi.org/10.1101/2021.09.14.21263589; this version posted September 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY 4.0 International license .

1148 35. Ronca R, Kotsyfakis M, Lombardo F, Rizzo C, Currà C, Ponzi M, Fiorentino G, Ribeiro JM, Arcà B.
1149 The Anopheles gambiae cE5, a tight- and fast-binding thrombin inhibitor with post-transcriptionally regulated
1150 salivary-restricted expression. Insect Biochem Mol Biol. 2012;42(9):610-20. doi: 10.1016/j.ibmb.2012.04.008.

1151 36. Sarr JB, Remoue F, Samb B, Dia I, Guindo S, Sow C, Maiga S, Tine S, Thiam C, Schacht AM, Simondon

- F, Konate L, Riveau G. Evaluation of antibody response to Plasmodium falciparum in children according to
 exposure of Anopheles gambiae s.l or Anopheles funestus vectors. Malar J. 2007;6. doi: 10.1186/1475-2875-6117.
- 37. Scarpassa VM, Debat HJ, Alencar RB, Saraiva JF, Calvo E, Arcà B, Ribeiro JMC. An insight into the
 sialotranscriptome and virome of Amazonian anophelines. BMC Genomics. 2019;20(1):166. doi:
 10.1186/s12864-019-5545-0.
- 38. Wells MB, Andrew DJ. Salivary gland cellular architecture in the Asian malaria vector mosquito
 Anopheles stephensi. Parasit Vectors. 2015;8:617-.
- 39. Zocevic A, Carmi-Leroy A, Sautereau J, d'Alayer J, Lenormand P, Rousselle JC, Namane A, Choumet
 V. New markers in Anopheles gambiae salivary glands after Plasmodium berghei infection. Vector Borne
 Zoonotic Dis. 2013;13(2):119-27. doi: 10.1089/vbz.2012.0964.
- 1163 The mal ERARCPoTfME. malERA: An updated research agenda for diagnostics, drugs, vaccines, and 40. 1164 vector control in malaria elimination and eradication. PLoS Med. 2017;14(11). doi: 1165 10.1371/journal.pmed.1002455.
- 1166 41. The mal ERARCPoBS, Enabling T. malERA: An updated research agenda for basic science and enabling 1167 elimination eradication. PLoS technologies malaria and Med. 2017;14(11). in doi: 1168 10.1371/journal.pmed.1002451.
- 1169 42. The mal ERARCPoCtR, Measuring T. malERA: An updated research agenda for characterising the
 1170 reservoir and measuring transmission in malaria elimination and eradication. PLoS Med. 2017;14(11). doi:
 1171 10.1371/journal.pmed.1002452.
- Andrade BB, Barral-Netto M. Biomarkers for susceptibility to infection and disease severity in human
 malaria. Mem Inst Oswaldo Cruz. 2011;106:70-8. doi: 10.1590/s0074-02762011000900009. PubMed PMID:
 WOS:000294440600009.
- 44. Andrade BB, Teixeira CR, Barral A, Barral-Netto M. Haematophagous arthropod saliva and host defense
 system: A tale of tear and blood. An Acad Bras Cienc. 2005;77(4):665-93. doi: 10.1590/S000137652005000400008.
- 1178 45. Billingsley PF, Baird J, Mitchell JA, Drakeley C. Immune interactions between mosquitoes and their
 1179 hosts. Parasite Immunol. 2006;28(4):143-53. doi: 10.1111/j.1365-3024.2006.00805.x. PubMed PMID:
 1180 WOS:000236064500004.
- 46. Cantillo JF, Fernández-Caldas E, Puerta L. Immunological aspects of the immune response induced by
 mosquito allergens. Int Arch Allergy Immunol. 2014;165(4):271-82. doi: 10.1159/000371349.
- 1183 47. Coutinho-Abreu IV, Guimaraes-Costa AB, Valenzuela JG. Impact of insect salivary proteins in blood
 1184 feeding, host immunity, disease, and in the development of biomarkers for vector exposure. Curr Opin Insect.
 1185 2015;10:98-103. doi: 10.1016/j.cois.2015.04.014. PubMed PMID: WOS:000369017500015.
- 48. Domingos A, Pinheiro-Silva R, Couto J, do Rosário V, de la Fuente J. The Anopheles gambiae
 transcriptome a turning point for malaria control. Insect Mol Biol. 2017;26(2):140-51. doi: 10.1111/imb.12289.
 49. Doucoure S, Cornelie S, Drame PM, Marie A, Ndille EE, Mathieu-Daudé F, Mouchet F, Poinsignon A,
- 1188 49. Doucoure S, Connene S, Drame FM, Marie A, Nume EE, Mathieu-Daude F, Mouchet F, Fonsignon A,
 1189 Remoue F. Biomarkers of vector bites: Arthropod immunogenic salivary proteins in vector-borne diseases control.
- In: Preedy VR, Patel VB, editors. General Methods in Biomarker Research and their Applications. 2-22015. p.
 1191 1177-205.
- 1192 50. Doucoure S, Drame PM. Salivary Biomarkers in the Control of Mosquito-Borne Diseases. Insects.
 1193 2015;6(4):961-76. doi: 10.3390/insects6040961.
- 1194 51. Drame PM, Poinsignon A, Marie A, Noukpo H, Doucoure S, Cornelie S, Remoue F, Manguin S. New
 1195 Salivary Biomarkers of Human Exposure to Malaria Vector Bites. In: Manguin S, editor. Anopheles mosquitoes:
 1196 New insights into malaria vectors2013. p. 755-95.
- 52. Fontaine A, Diouf I, Bakkali N, Missé D, Pagès F, Fusai T, Rogier C, Almeras L. Implication of
 haematophagous arthropod salivary proteins in host-vector interactions. Parasit Vectors. 2011;4(1). doi:
 10.1186/1756-3305-4-187.
- Foy BD, Killeen GF, Magalhaes T, Beier JC. Immunological targeting of critical insect antigens. Am
 Entomol. 2002;48(3):150-62. doi: 10.1093/ae/48.3.150.
- 1202 54. Gillespie RD, Mbow ML, Titus RG. The immunomodulatory factors of bloodfeeding arthropod saliva.
 1203 Parasite Immunol. 2000;22(7):319-31. doi: 10.1046/j.1365-3024.2000.00309.x.

perpetuity. It is made available under a CC-BY 4.0 International license .

- 1204 55. Hopp CS, Sinnis P. The innate and adaptive response to mosquito saliva and Plasmodium sporozoites in
 1205 the skin. Ann N Y Acad Sci. 2015;1342:37-43. doi: 10.1111/nyas.12661. PubMed PMID:
 1206 WOS:000353102900005.
- 1207 56. Hugo RLE, Birrell GW. Proteomics of Anopheles Vectors of Malaria. Trends Parasitol.
 1208 2018;34(11):961-81. doi: 10.1016/j.pt.2018.08.009.
- 1209 57. Leitner WW, Denis ACS, Wali T. Immunological consequences of arthropod vector-derived salivary
 1210 factors. Eur J Immunol. 2011;41(12):3396-400. doi: 10.1002/eji.201190075.
- 1211 58. Lombardo F, Lanfrancotti A, Mestres-Simón M, Rizzo C, Coluzzi M, Arcà B. At the interface between
- parasite and host: The salivary glands of the African malaria vector Anopheles gambiae. Parassitologia.
 2006;48(4):573-80.
- 1214 59. Mathema VB, Na-Bangchang K. A brief review on biomarkers and proteomic approach for malaria 1215 research. Asian Pac J Trop Med. 2015;8(4):253-62. doi: 10.1016/S1995-7645(14)60327-8.
- 1216 60. Peng Z, Estelle F, Simons R. Mosquito allergy and mosquito salivary allergens. Protein Peptide Lett.
 1217 2007;14(10):975-81. doi: 10.2174/092986607782541088. PubMed PMID: WOS:000253577700007.
- Ribeiro JMC, Francischetti IMB. Role of Arthropod Saliva in Blood Feeding: Sialome and Post-Sialome
 Perspectives. Annu Rev Entomol. 2003;48:73-88. doi: 10.1146/annurev.ento.48.060402.102812.
- Sagna A, Poinsignon A, Remoue F, Wikel SK, Aksoy S, Dimopoulos G. Epidemiological Applications
 of Assessing Mosquito Exposure in a Malaria-Endemic Area. In: Wikel SK, Dimopoulos G, Aksoy S, editors.
 Arthropod Vector: Controller of Disease Transmission, Volume 2: Vector Saliva-Host Pathogen Interactions2017.
 p. 209-29.
- 1224 63. Sá-Nunes A, De Oliveira CJF. Sialogenins and immunomodulators derived from blood feeding parasites.
 1225 In: Kini R, Clemetson K, Markland F, McLane M, Morita T, editors. Toxins and Hemostasis2011. p. 131-52.
- 1226 64. Miot HA, Lima HC. Allergy to Hematophagous Arthropods Bites. Current Dermatology Reports.
 1227 2014;3(1):6-12.
- Peng Z, Simons FER. Mosquito allergy: immune mechanisms and recombinant salivary allergens. Int
 Arch Allergy Appl Immunol. 2004;133(2):198-209.
- 1230 66. Pingen M, Schmid MA, Harris E, McKimmie CS. Mosquito biting modulates skin response to virus 1231 infection. Trends Parasitol. 2017;33(8):645-57.
- 1232 67. Sinden RE, Blagborough AM, Churcher T, Ramakrishnan C, Biswas S, Delves MJ. The design and
 1233 interpretation of laboratory assays measuring mosquito transmission of Plasmodium. Trends Parasitol.
 1234 2012;28(11):457-65.
- 1235 68. Abonuusum A, Owusu-Daako K, Tannich E, May J, Garms R, Kruppa T. Malaria transmission in two
 1236 rural communities in the forest zone of Ghana. Parasitol Res. 2011;108(6):1465-71. doi: 10.1007/s00436-0101237 2195-1.
- Badu K, Afrane YA, Larbi J, Stewart VA, Waitumbi J, Angov E, Ong'echa JM, Perkins DJ, Zhou G,
 Githeko A, Yan G. Marked variation in MSP-1 19antibody responses to malaria in western Kenyan highlands.
 BMC Infect Dis. 2012;12. doi: 10.1186/1471-2334-12-50.
- 1241 70. Chaccour CJ, Kobylinski KC, Bassat Q, Bousema T, Drakeley C, Alonso P, Foy BD. Ivermectin to
 1242 reduce malaria transmission: A research agenda for a promising new tool for elimination. Malar J. 2013;12(1).
 1243 doi: 10.1186/1475-2875-12-153.
- 1244 71. Coulibaly D, Travassos MA, Tolo Y, Laurens MB, Kone AK, Traore K, Sissoko M, Niangaly A, Diarra
- I, Daou M, Guindo B, Rebaudet S, Kouriba B, Dessay N, Piarroux R, Plowe CV, Doumbo OK, Thera MA, Gaudart
 J. Spatio-temporal dynamics of asymptomatic malaria: Bridging the gap between annual Malaria resurgences in
- 1247 a Sahelian environment. Am J Trop Med Hyg. 2017;97(6):1761-9. doi: 10.4269/ajtmh.17-0074.
- 1248 72. Dhawan R, Kumar M, Mohanty AK, Dey G, Advani J, Prasad TSK, Kumar A. Mosquito-borne diseases
 1249 and omics: Salivary gland proteome of the female aedes aegypti mosquito. OMICS: J Integrative Biol.
 1250 2017;21(1):45-54. doi: 10.1089/omi.2016.0160.
- 1251 73. Fontaine A, Pascual A, Diouf I, Bakkali N, Bourdon S, Fusai T, Rogier C, Almeras L. Mosquito salivary
 1252 gland protein preservation in the field for immunological and biochemical analysis. Parasit Vectors. 2011;4:33.
 1253 doi: 10.1186/1756-3305-4-33.
- 1254 74. Fontaine A, Pascual A, Orlandi-Pradines E, Diouf I, Remoue F, Pages F, Fusai T, Rogier C, Almeras L.
 1255 Relationship between Exposure to Vector Bites and Antibody Responses to Mosquito Salivary Gland Extracts.
 1256 PLoS One. 2011;6(12). doi: 10.1371/journal.pone.0029107. PubMed PMID: WOS:000298369100156.
- 1257 75. Jeon SH, Park JW, Lee BH. Characterization of human IgE and mouse IgG1 responses to allergens in
- three mosquito species by immunoblotting and ELISA. Int Arch Allergy Immunol. 2001;126(3):206-12. doi: 10.1159/000049515.

medRxiv preprint doi: https://doi.org/10.1101/2021.09.14.21263589; this version posted September 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY 4.0 International license .

1260 76. Kelly-Hope LA, McKenzie FE. The multiplicity of malaria transmission: A review of entomological
1261 inoculation rate measurements and methods across sub-Saharan Africa. Malar J. 2009;8(1). doi: 10.1186/14751262 2875-8-19.

1263 77. Kusi KA, Bosomprah S, Dodoo D, Kyei-Baafour E, Dickson EK, Mensah D, Angov E, Dutta S, Sedegah
1264 M, Koram KA. Anti-sporozoite antibodies as alternative markers for malaria transmission intensity estimation.
1265 Malar J. 2014;13(1). doi: 10.1186/1475-2875-13-103.

1266 78. Li B, Calvo E, Marinotti O, James AA, Paskewitz SM. Characterization of the c-type lysozyme gene
1267 family in Anopheles gambiae. Gene. 2005;360(2):131-9. doi: 10.1016/j.gene.2005.07.001.

1268 79. Londono-Renteria B, Patel JC, Vaughn M, Funkhauser S, Ponnusamy L, Grippin C, Jameson SB,
1269 Apperson C, Mores CN, Wesson DM, Colpitts TM, Meshnick SR. Long-lasting permethrin-impregnated clothing
1270 protects against mosquito bites in outdoor workers. Am J Trop Med Hyg. 2015;93(4):869-74. doi:
1271 10.4269/ajtmh.15-0130.

1272 80. Mwanziva C, Manjurano A, Mbugi E, Mweya C, Mkali H, Kivuyo MP, Sanga A, Ndaro A, Chambo W,
1273 Mkwizu A, Kitau J, Kavishe R, Dolmans W, Chilongola J, Mosha FW. Defining malaria burden from morbidity
1274 and mortality records, self treatment practices and serological data in Magugu, Babati district, northern Tanzania.
1275 Tanzan J Health Res. 2011;13(2). doi: 10.4314/thrb.v13i2.62980.

1276 81. Sarr J, Orlandi-Pradines E, Fortin S, Sow C, Cornelie S, Rogerie F, Guindo S, Konate L, Fusa T, Riveau
1277 G, Rogier C, Remoue F. Assessment of exposure to Plasmodium falciparum transmission in a low endemicity
1278 area by using multiplex fluorescent microsphere-based serological assays. Parasit Vectors. 2011;4(1). doi:
1279 10.1186/1756-3305-4-212.

1280 82. Satoguina J, Walther B, Drakeley C, Nwakanma D, Oriero EC, Correa S, Corran P, Conway DJ, Walther
1281 M. Comparison of surveillance methods applied to a situation of low malaria prevalence at rural sites in the
1282 Gambia and Guinea Bissau. Malar J. 2009;8(1). doi: 10.1186/1475-2875-8-274.

1283 83. Smithuis FM, Kyaw MK, Phe UO, Van Der Broek I, Katterman N, Rogers C, Almeida P, Kager PA,
1284 Stepniewska K, Lubell Y, Simpson JA, White NJ. Entomological determinants of insecticide-treated bed net
1285 effectiveness in Western Myanmar. Malar J. 2013;12(1). doi: 10.1186/1475-2875-12-364.

1286 84. Ubillos I, Campo JJ, Jiménez A, Dobaño C. Development of a high-throughput flexible quantitative
1287 suspension array assay for IgG against multiple Plasmodium falciparum antigens. Malar J. 2018;17(1). doi:
1288 10.1186/s12936-018-2365-7.

1289 85. van den Hoogen LL, Présumé J, Romilus I, Mondélus G, Elismé T, Sepúlveda N, Stresman G, Druetz T,
1290 Ashton RA, Joseph V, Eisele TP, Hamre KES, Chang MA, Lemoine JF, Tetteh KKA, Boncy J, Existe A, Drakeley
1291 C, Rogier E. Quality control of multiplex antibody detection in samples from large-scale surveys: the example of
1292 malaria in Haiti. Sci Rep. 2020;10(1). doi: 10.1038/s41598-020-57876-0.

1293 86. Varela ML, Koffi D, White M, Niang M, Mbengue B, Diene Sarr F, Touré AO, Perraut R. Practical
1294 example of multiple antibody screening for evaluation of malaria control strategies. Malar J. 2020;19(1). doi:
1295 10.1186/s12936-020-03186-9.

1296 87. Wanjala CL, Kweka EJ. Impact of highland topography changes on exposure to malaria vectors and
1297 immunity in Western Kenya. Front Public Health. 2016;4(OCT). doi: 10.3389/FPUBH.2016.00227.

1298 88. Armiyanti Y, Arifianto RP, Riana EN, Senjarini K, Widodo W, Fitri LE, Sardjono TW. Identification of
1299 antigenic proteins from salivary glands of female Anopheles maculatus by proteomic analysis. Asian Pac J Trop
1300 Biomed. 2016;6(11):924-30. doi: 10.1016/j.apjtb.2016.08.012.

1301 89. Brummer-Korvenkontio H, Palosuo T, François G, Reunala T. Characterization of Aedes communis,
1302 Aedes aegypti and Anopheles stephensi mosquito saliva antigens by immunoblotting. Int Arch Allergy Immunol.
1303 1997;112(2):169-74. doi: 10.1159/000237450.

1304 90. Cornelie S, Remoue F, Doucoure S, Ndiaye T, Sauvage FX, Boulanger D, Simondon F. An insight into
1305 immunogenic salivary proteins of Anopheles gambiae in African children. Malar J. 2007;6:75. doi: 10.1186/14751306 2875-6-75.

1307 91. Fontaine A, Fusaï T, Briolant S, Buffet S, Villard C, Baudelet E, Pophillat M, Granjeaud S, Rogier C,
1308 Almeras L. Anopheles salivary gland proteomes from major malaria vectors. BMC Genomics. 2012;13:614. doi:
1309 10.1186/1471-2164-13-614.

Marie A, Holzmuller P, Tchioffo MT, Rossignol M, Demettre E, Seveno M, Corbel V, Awono-Ambéné
P, Morlais I, Remoue F, Cornelie S. Anopheles gambiae salivary protein expression modulated by wild
Plasmodium falciparum infection: highlighting of new antigenic peptides as candidates of An. gambiae bites.
Parasit Vectors. 2014;7:599. doi: 10.1186/s13071-014-0599-y.

1314 93. Owhashi M, Harada M, Suguri S, Omae H, Ishii A. Identification of an eosinophil chemotactic factor
1315 from anopheline mosquitoes as a chitinase family protein. Parasitol Res. 2008;102(3):357-63. doi:
1316 10.1007/s00436-007-0769-3.

perpetuity. It is made available under a CC-BY 4.0 International license .

1317 94. Penneys NS, Nayar JK, Bernstein H, Knight JW, Leonardi C. Mosquito Salivary Gland Antigens
1318 Identified by Circulating Human Antibodies. Arch Dermatol. 1989;125(2):219-22. doi:
1319 10.1001/archderm.1989.01670140071012.

1320 95. Sor-suwan S, Jariyapan N, Roytrakul S, Paemanee A, Phumee A, Phattanawiboon B, Intakhan N,
1321 Chanmol W, Bates PA, Saeung A, Choochote W. Identification of salivary gland proteins depleted after blood
1322 feeding in the malaria vector Anopheles campestris-like mosquitoes (Diptera: Culicidae). PLoS One.
1323 2014;9(3):e90809. doi: 10.1371/journal.pone.0090809.

Sor-Suwan S, Jariyapan N, Roytrakul S, Paemanee A, Saeung A, Thongsahuan S, Phattanawiboon B,
Bates PA, Poovorawan Y, Choochote W. Salivary gland proteome of the human malaria vector, Anopheles
campestris-like (Diptera: Culicidae). Parasitol Res. 2013;112(3):1065-75. doi: 10.1007/s00436-012-3233-y.

Peng ZK, Li HB, Simons FER. Immunoblot analysis of salivary allergens in 10 mosquito species with
worldwide distribution and the human IgE responses as these allergens. J Allergy Clin Immunol. 1998;101(4):498505. doi: 10.1016/s0091-6749(98)70357-4. PubMed PMID: WOS:000073113500012.

1330 98. Cornelie S, Senglat M, Doucoure S, Demettre E, Remoue F. Characterization of immunogenic proteins
1331 in *Anopheles gambiae* salivary glands and their potential use as a marker of exposure to malaria. Am J Trop Med
1332 Hyg. 2008;79(6):320-. PubMed PMID: WOS:000261644601456.

1333 99. Drame PM, Poinsignon A, Besnard P, Cornelie S, Foumane V, Sow CS, Le Mire J, Fortes F, Boulanger
1334 D, Carnevale P, Simondon F, Remoue F. Human antibody response to *Anopheles gambiae* saliva: A new immuno1335 epidemiological marker to evaluate the effectiveness of insecticides treated nets (ITNs)? Am J Trop Med Hyg.
1336 2008;79(6):358-. PubMed PMID: WOS:000261644601582.

1337 100. Drame PM, Poinsignon A, Besnard P, Cornelie S, Le Mire J, Fortes F, Toto JC, Sembene M, Simondon
1338 F, Carnevale P, Remoue F. Human antibody response to *Anopheles* salivary gSG6-P1 peptide: New immuno1339 epidemiological tool for evaluating the efficacy of insecticides treated nets (ITNs) in malaria vector control. Am
1340 J Trop Med Hyg. 2010;83(5):260-. PubMed PMID: WOS:000295819701240.

1341 101. Poinsignon A, Cornelie S, Mestres-Simon M, Lanfrancotti A, Rossignol M, Boulanger D, Cisse B,
1342 Sokhna C, Arca B, Simondon F, Remoue F. Human IgG response to *Anopheles gambiae* salivary proteins as an
1343 immuno-epidemiological marker of exposure to malaria vector bites. Am J Trop Med Hyg. 2008;79(6):218-.
1344 PubMed PMID: WOS:000261644601102.

1345 102. Poinsignon A, Drame PM, Marie A, Noukpo H, Cornelie S, Remoue F. Development of a biomarker of
exposure to *Anopheles* bites based on human antibody response to salivary proteins: From concept to application
in the field. Pathog Glob Health. 2013;107(8):455-. PubMed PMID: WOS:000335056200147.

1348 103. Poinsignon A, Drame PM, Samb B, Cornelie S, Sow C, Dia I, Riveau G, Konate L, Sokhna C, Remoue
1349 FJ. Development of a new biomarker of exposure to *Anopheles* bites based on human antibody responses to
1350 salivary proteins: From the concept to the applications. Am J Trop Med Hyg. 2010;83(5):184-. PubMed PMID:
1351 WOS:000295819700617.

1352 104. Sagna AB, Kassie D, Couvray A, Hermann E, Riveau G, Salem G, Fournet F, Remoue F. Spatial risk of
1353 urban exposure to *Anopheles* and *Aedes* mosquito bites in africa using salivary antibody-based biomarkers. Am J
1354 Trop Med Hyg. 2018;99(4):47-. PubMed PMID: WOS:000461386602150.

1355 105. Dragovic SM, Agunbiade TA, Freudzon M, Yang J, Hastings AK, Schleicher TR, Zhou X, Craft S,
1356 Chuang YM, Gonzalez F, Li Y, Hrebikova G, Tripathi A, Mlambo G, Almeras L, Ploss A, Dimopoulos G, Fikrig
1357 E. Immunization with AgTRIO, a Protein in Anopheles Saliva, Contributes to Protection against Plasmodium
1358 Infection in Mice. Cell Host Microbe. 2018;23(4):523-35.e5. doi: 10.1016/j.chom.2018.03.008.

1359 106. King JG, Vernicks KD, Hillyer JF. Members of the salivary gland surface protein (SGS) family are major
immunogenic components of mosquito saliva. J Biol Chem. 2011;286(47):40824-34. doi:
1361 10.1074/jbc.M111.280552.

1362 107. Vogt MB, Lahon A, Arya RP, Kneubehl AR, Spencer Clinton JL, Paust S, Rico-Hesse R. Mosquito
1363 saliva alone has profound effects on the human immune system. PLoS Negl Trop Dis. 2018;12(5). doi:
1364 10.1371/journal.pntd.0006439.

1365 108. Wang J, Zhang Y, Zhao YO, Li MW, Zhang L, Dragovic S, Abraham NM, Fikrig E. Anopheles gambiae
 1366 circumsporozoite protein-binding protein facilitates plasmodium infection of mosquito salivary glands. J Infect
 1367 Dis. 2013;208(7):1161-9. doi: 10.1093/infdis/jit284.

1368109.Almeida AP, Billingsley PF. Induced immunity against the mosquito Anopheles stephensi: reactivity1369characteristics of immune sera. Med Vet Entomol. 1999;13(1):53-64. doi: 10.1046/j.1365-2915.1999.00143.x.

1370 110. Boulanger D, Doucoure S, Grout L, Ngom A, Rogerie F, Cornelie S, Sokhna C, Mouchet F, Riveau G,

Simondon F, Remoue FJ. Immunoglobulin G antibody profiles against Anopheles salivary proteins in domestic
 animals in Senegal. J Med Entomol. 2011;48(3):691-3. doi: 10.1603/me10183.

1372 animals in Senegal. J Med Entomol. 2011;48(3):691-3. doi: 10.1603/me1013

1373 111. Kerkhof K, Canier L, Kim S, Heng S, Sochantha T, Sovannaroth S, Vigan-Womas I, Coosemans M,
1374 Sluydts V, Ménard D, Durnez L. Implementation and application of a multiplex assay to detect malaria-specific

medRxiv preprint doi: https://doi.org/10.1101/2021.09.14.21263589; this version posted September 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

1375 antibodies: a promising tool for assessing malaria transmission in Southeast Asian pre-elimination areas. Malar J. 1376 2015;14:338. doi: 10.1186/s12936-015-0868-z.

1377 112. Sagna AB, Gaaveb L, Sarr JB, Senghor S, Poinsignon A, Boutouaba-Combe S, Schacht AM, Hermann

1378 E, Faye N, Remoue F, Riveau G. Plasmodium falciparum infection during dry season: IgG responses to Anopheles

1379 gambiae salivary gSG6-P1 peptide as sensitive biomarker for malaria risk in Northern Senegal. Malar J. 1380 2013;12:301. doi: 10.1186/1475-2875-12-301.

1381 113. Ya-Umphan P, Cerqueira D, Cottrell G, Parker DM, Fowkes FJI, Nosten F, Corbel V. Anopheles salivary 1382 biomarker as a proxy for estimating *Plasmodium falciparum* malaria exposure on the Thailand-Myanmar Border. 1383 Am J Trop Med Hyg. 2018;99(2):350-6.

1384 114. Aka KG, Traoré DF, Sagna AB, Zoh DD, Assi SB, Tchiekoi BN, Adja AM, Remoue F, Poinsignon A. 1385 Pattern of antibody responses to Plasmodium falciparum antigens in individuals differentially exposed to 1386 Anopheles bites. Malar J. 2020;19(1):83. doi: 10.1186/s12936-020-03160-5.

1387 115. Drame PM, Diallo A, Poinsignon A, Boussari O, Dos Santos S, Machault V, Lalou R, Cornelie S, 1388 LeHesran JY, Remoue F. Evaluation of the effectiveness of malaria vector control measures in urban settings of 1389 PLoS Dakar bv а specific Anopheles salivary biomarker. One. 2013;8(6):e66354. doi: 1390 10.1371/journal.pone.0066354.

1391 116. Londono-Renteria BL, Eisele TP, Keating J, James MA, Wesson DM. Antibody response against 1392 Anopheles albimanus (Diptera: Culicidae) salivary protein as a measure of mosquito bite exposure in Haiti. J Med 1393 Entomol. 2010;47(6):1156-63. doi: 10.1603/me09240.

1394 Noukpo MH, Damien GB, Elanga-N'Dille E, Sagna AB, Drame PM, Chaffa E, Boussari O, Corbel V, 117. 1395 Akogbéto M, Remoue F. Operational assessment of long-lasting insecticidal nets by using an Anopheles salivary 1396

biomarker of human-vector contact. Am J Trop Med Hyg. 2016;95(6):1376-82. doi: 10.4269/ajtmh.15-0541.

1397 Manning JE, Oliveira F, Coutinho-Abreu IV, Herbert S, Meneses C, Kamhawi S, Baus HA, Han A, 118. 1398 Czajkowski L, Rosas LA, Cervantes-Medina A, Athota R, Reed S, Mateja A, Hunsberger S, James E, 1399 Pleguezuelos O, Stoloff G, Valenzuela JG, Memoli MJ. Safety and immunogenicity of a mosquito saliva peptide-1400 based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial. Lancet. 2020;395(10242):1998-1401 2007. doi: 10.1016/S0140-6736(20)31048-5. PubMed PMID: ClinicalTrials.gov/NCT03055000.

1402 119. Mendes-Sousa AF, Vale VF, Queiroz DC, Pereira-Filho AA, da Silva NCS, Koerich LB, Moreira LA, 1403 Pereira MH, Sant'Anna MR, Araújo RN, Andersen J, Valenzuela JG, Gontijo NF. Inhibition of the complement 1404 system by saliva of Anopheles (Nyssorhynchus) aquasalis. Insect Biochem Mol Biol. 2018;92:12-20. doi: 1405 10.1016/j.ibmb.2017.11.004.

1406 120. Peng Z, Beckett AN, Engler RJ, Hoffman DR, Ott NL, Simons FE. Immune responses to mosquito saliva 1407 in 14 individuals with acute systemic allergic reactions to mosquito bites. J Allergy Clin Immunol. 1408 2004;114(5):1189-94. doi: 10.1016/j.jaci.2004.08.014.

1409 Londono-Renteria B, Cardenas JC, Troupin A, Colpitts TM. Natural mosquito-pathogen hybrid IgG4 121. 1410 antibodies in vector-borne diseases: А hypothesis. Front Immunol. 2016;7(SEP). doi: 1411 10.3389/fimmu.2016.00380.

1412 Owhashi M, Harada M, Suguri S, Ohmae H, Ishii A. The role of saliva of Anopheles stephensi in 122. 1413 inflammatory response: identification of a high molecular weight neutrophil chemotactic factor. Parasitol Res. 1414 2001;87(5):376-82. doi: 10.1007/s004360000355.

1415 Armiyanti Y, Nuryady MM, Arifianto RP, Nurmariana E, Senjarini K, Fitri LE, Sardjono TW. Detection 123. 1416 of immunogenic proteins from Anopheles sundaicus salivary glands. Revista da Sociedade Brasileira de Medicina 1417 Tropical. 2015;48(4):410-6. doi: 10.1590/0037-8682-0185-2015.

1418 Opasawatchai A, Yolwong W, Thuncharoen W, Inrueangsri N, Itsaradisaikul S, Sasisakulporn C, 124. 1419 Jotikasthira W, Matangkasombut O, Reamtong O, Manuyakorn W, Songnuan W, Matangkasombut P. Novel 1420 salivary gland allergens from tropical mosquito species and IgE reactivity in allergic patients. World Allergy 1421 Organ J. 2020;13(2). doi: 10.1016/j.waojou.2020.100099.

1422 125. Orlandi-Pradines E, Almeras L, Denis de Senneville L, Barbe S, Remoué F, Villard C, Cornelie S,

1423 Penhoat K, Pascual A, Bourgouin C, Fontenille D, Bonnet J, Corre-Catelin N, Reiter P, Pagés F, Laffite D,

1424 Boulanger D, Simondon F, Pradines B, Fusaï T, Rogier C. Antibody response against saliva antigens of Anopheles 1425 gambiae and Aedes aegypti in travellers in tropical Africa. Microbes Infect. 2007;9(12-13):1454-62. doi: 1426 10.1016/j.micinf.2007.07.012.

1427 Ambrosino E, Dumoulin C, Orlandi-Pradines E, Remoue F, Toure-Baldé A, Tall A, Sarr JB, Poinsignon 126.

1428 A, Sokhna C, Puget K, Trape JF, Pascual A, Druilhe P, Fusai T, Rogier C. A multiplex assay for the simultaneous 1429 detection of antibodies against 15 Plasmodium falciparum and Anopheles gambiae saliva antigens. Malar J.

1430 2010;9:317. doi: 10.1186/1475-2875-9-317. medRxiv preprint doi: https://doi.org/10.1101/2021.09.14.21263589; this version posted September 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .

1431 127. Kerkhof K, Sluydts V, Willen L, Kim S, Canier L, Heng S, Tsuboi T, Sochantha T, Sovannaroth S,
1432 Ménard D, Coosemans M, Durnez L. Serological markers to measure recent changes in malaria at population
1433 level in Cambodia. Malar J. 2016;15(1):1-18. doi: 10.1186/s12936-016-1576-z.

1434 128. Koffi D, Touré AO, Varela ML, Vigan-Womas I, Béourou S, Brou S, Ehouman MF, Gnamien L, Richard
1435 V, Djaman JA, Perraut R. Analysis of antibody profiles in symptomatic malaria in three sentinel sites of Ivory
1436 Coast by using multiplex, fluorescent, magnetic, bead-based serological assay (MAGPIXTM). Malar J.
1437 2015;14:509. doi: 10.1186/s12936-015-1043-2.

1438 129. Koffi D, Varela ML, Loucoubar C, Beourou S, Vigan-Womas I, Touré A, Djaman JA, Touré AO, Perraut
1439 R. Longitudinal analysis of antibody responses in symptomatic malaria cases do not mirror parasite transmission
1440 in peri-urban area of Cote d'Ivoire between 2010 and 2013. PLoS One. 2017;12(2):e0172899. doi:
10.1371/journal.pone.0172899.

1442 130. Perraut R, Varela ML, Loucoubar C, Niass O, Sidibé A, Tall A, Trape JF, Wotodjo AN, Mbengue B,
1443 Sokhna C, Vigan-Womas I, Touré A, Richard V, Mercereau-Puijalon O. Serological signatures of declining
1444 exposure following intensification of integrated malaria control in two rural Senegalese communities. PLoS One.
1445 2017;12(6):e0179146. doi: 10.1371/journal.pone.0179146.

1446 131. Proietti C, Verra F, Bretscher MT, Stone W, Kanoi BN, Balikagala B, Egwang TG, Corran P, Ronca R,
1447 Arcà B, Riley EM, Crisanti A, Drakeley C, Bousema T. Influence of infection on malaria-specific antibody
1448 dynamics in a cohort exposed to intense malaria transmission in northern Uganda. Parasite Immunol. 2013;35(51449 6):164-73. doi: 10.1111/pim.12031.

1450 132. Stone W, Bousema T, Jones S, Gesase S, Hashim R, Gosling R, Carneiro I, Chandramohan D, Theander
1451 T, Ronca R, Modiano D, Arcà B, Drakeley C. IgG responses to *Anopheles gambiae* salivary antigen gSG6 detect
1452 variation in exposure to malaria vectors and disease risk. PLoS One. 2012;7(6):e40170. doi:
10.1371/journal.pone.0040170.

1454 133. Ya-Umphan P, Cerqueira D, Parker DM, Cottrell G, Poinsignon A, Remoue F, Brengues C,
1455 Chareonviriyaphap T, Nosten F, Corbel V. Use of an *Anopheles* salivary biomarker to assess malaria transmission
1456 risk along the Thailand-Myanmar Border. J Infect Dis. 2017;215(3):396-404. doi: 10.1093/infdis/jiw543.

1457 134. Idris ZM, Chan CW, Mohammed M, Kalkoa M, Taleo G, Junker K, Arcà B, Drakeley C, Kaneko A.
1458 Serological measures to assess the efficacy of malaria control programme on Ambae Island, Vanuatu. Parasit
1459 Vectors. 2017;10(1):204. doi: 10.1186/s13071-017-2139-z.

1460 135. Yman V, White MT, Rono J, Arca B, Osier FH, Troye-Blomberg M, Bostrom S, Ronca R, Rooth I,
1461 Farnert A. Antibody acquisition models: A new tool for serological surveillance of malaria transmission intensity.
1462 Sci Rep. 2016;6. doi: 10.1038/srep19472. PubMed PMID: WOS:000369380100001.

1463 136. Badu K, Gyan B, Appawu M, Mensah D, Dodoo D, Yan G, Drakeley C, Zhou G, Owusu-Dabo E, Koram
1464 KA. Serological evidence of vector and parasite exposure in Southern Ghana: the dynamics of malaria
1465 transmission intensity. Parasit Vectors. 2015;8:251. doi: 10.1186/s13071-015-0861-y.

1466 137. Sarr JB, Samb B, Sagna AB, Fortin S, Doucoure S, Sow C, Senghor S, Gaayeb L, Guindo S, Schacht
1467 AM, Rogerie F, Hermann E, Dia I, Konate L, Riveau G, Remoue F. Differential acquisition of human antibody
1468 responses to *Plasmodium falciparum* according to intensity of exposure to *Anopheles* bites. Trans R Soc Trop
1469 Med Hyg. 2012;106(8):460-7. doi: 10.1016/j.trstmh.2012.05.006.

1470 138. Drame PM, Poinsignon A, Dechavanne C, Cottrell G, Farce M, Ladekpo R, Massougbodji A, Cornélie
1471 S, Courtin D, Migot-Nabias F, Garcia A, Remoué F. Specific antibodies to *Anopheles* gSG6-P1 salivary peptide
1472 to assess early childhood exposure to malaria vector bites. Malar J. 2015;14:285. doi: 10.1186/s12936-015-08001473 6.

1474 139. Ali ZM, Bakli M, Fontaine A, Bakkali N, Vu Hai V, Audebert S, Boublik Y, Pagès F, Remoué F, Rogier
1475 C, Fraisier C, Almeras L. Assessment of *Anopheles* salivary antigens as individual exposure biomarkers to
1476 species-specific malaria vector bites. Malar J. 2012;11:439. doi: 10.1186/1475-2875-11-439.

1477 140. Rizzo C, Ronca R, Fiorentino G, Mangano VD, Sirima SB, Nèbiè I, Petrarca V, Modiano D, Arcà B.
1478 Wide cross-reactivity between *Anopheles gambiae* and *Anopheles funestus* SG6 salivary proteins supports
1479 exploitation of gSG6 as a marker of human exposure to major malaria vectors in tropical Africa. Malar J.
1480 2011;10:206. doi: 10.1186/1475-2875-10-206.

1481 141. Poinsignon A, Cornelie S, Mestres-Simon M, Lanfrancotti A, Rossignol M, Boulanger D, Cisse B, 1482 Sokhna C, Arcà B, Simondon F, Remoue F. Novel peptide marker corresponding to salivary protein gSG6 1483 potentially identifies exposure to Anopheles bites. PLoS One. 2008;3(6):e2472. doi: 1484 10.1371/journal.pone.0002472.

1485 142. Rizzo C, Lombardo F, Ronca R, Mangano V, Sirima SB, Nèbiè I, Fiorentino G, Modiano D, Arcà B.
1486 Differential antibody response to the *Anopheles gambiae* gSG6 and cE5 salivary proteins in individuals naturally
1487 exposed to bites of malaria vectors. Parasit Vectors. 2014;7:549. doi: 10.1186/s13071-014-0549-8.

medRxiv preprint doi: https://doi.org/10.1101/2021.09.14.21263589; this version posted September 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY 4.0 International license .

1488 143. Drame PM, Poinsignon A, Besnard P, Le Mire J, Dos-Santos MA, Sow CS, Cornelie S, Foumane V,
1489 Toto JC, Sembene M, Boulanger D, Simondon F, Fortes F, Carnevale P, Remoue F. Human antibody response to
1490 *Anopheles gambiae* saliva: an immuno-epidemiological biomarker to evaluate the efficacy of insecticide-treated
1491 nets in malaria vector control. Am J Trop Med Hyg. 2010;83(1):115-21. doi: 10.4269/ajtmh.2010.09-0684.

1492 144. Remoue F, Cisse B, Ba F, Sokhna C, Herve JP, Boulanger D, Simondon F. Evaluation of the antibody
1493 response to *Anopheles* salivary antigens as a potential marker of risk of malaria. Trans R Soc Trop Med Hyg.
1494 2006;100(4):363-70. doi: 10.1016/j.trstmh.2005.06.032.

1495 145. Lawaly R, Konate L, Marrama L, Dia I, Diallo D, Sarr FD, Schneider BS, Casademont I, Diallo M, Brey
1496 PT, Sakuntabhai A, Mecheri S, Paul R. Impact of mosquito bites on asexual parasite density and gametocyte
1497 prevalence in asymptomatic chronic *Plasmodium falciparum* infections and correlation with IgE and IgG titers.
1498 Infect Immun. 2012;80(6):2240-6. doi: 10.1128/iai.06414-11. PubMed PMID: WOS:000304387700031.

1499 146. Rizzo C, Ronca R, Lombardo F, Mangano V, Sirima SB, Nèbiè I, Fiorentino G, Troye-Blomberg M,
1500 Modiano D, Arcà B. IgG1 and IgG4 antibody responses to the *Anopheles gambiae* salivary protein gSG6 in the
1501 sympatric ethnic groups Mossi and Fulani in a malaria hyperhendemic area of Burkina Faso. PLoS One.
1502 2014;9(4):e96130. doi: 10.1371/journal.pone.0096130.

1503 147. Marie A, Ronca R, Poinsignon A, Lombardo F, Drame PM, Cornelie S, Besnard P, Le Mire J, Fiorentino
1504 G, Fortes F, Carnevale P, Remoue F, Arcà B. The *Anopheles gambiae* cE5 salivary protein: a sensitive biomarker
1505 to evaluate the efficacy of insecticide-treated nets in malaria vector control. Microbes Infect. 2015;17(6):409-16.
1506 doi: 10.1016/j.micinf.2015.01.002.

1507 148. Brosseau L, Drame PM, Besnard P, Toto JC, Foumane V, Le Mire J, Mouchet F, Remoue F, Allan R,
1508 Fortes F, Carnevale P, Manguin S. Human antibody response to *Anopheles* saliva for comparing the efficacy of
1509 three malaria vector control methods in Balombo, Angola. PLoS One. 2012;7(9):e44189. doi:
1510 10.1371/journal.pone.0044189.

1511 149. Londono-Renteria B, Drame PM, Montiel J, Vasquez AM, Tobón-Castaño A, Taylor M, Vizcaino L,
1512 Lenhart AAE. Identification and pilot evaluation of salivary peptides from *Anopheles albimanus* as biomarkers
1513 for bite exposure and malaria infection in Colombia. Int J Mol Sci. 2020;21(3). doi: 10.3390/ijms21030691.

1514 150. Andrade BB, Rocha BC, Reis-Filho A, Camargo LM, Tadei WP, Moreira LA, Barral A, Barral-Netto 1515 M. Anti-*Anopheles darlingi* saliva antibodies as marker of *Plasmodium vivax* infection and clinical immunity in

the Brazilian Amazon. Malar J. 2009;8:121. doi: 10.1186/1475-2875-8-121.
1517 151. Waitayakul A, Somsri S, Sattabongkot J, Looareesuwan S, Cui L, Udomsangpetch R. Natural human humoral response to salivary gland proteins of *Anopheles* mosquitoes in Thailand. Acta Trop. 2006;98(1):66-73.

1519 doi: 10.1016/j.actatropica.2006.02.004.

1520 152. Montiel J, Carbal LF, Tobón-Castaño A, Vásquez GM, Fisher ML, Londono-Rentería B. IgG antibody
1521 response against *Anopheles* salivary gland proteins in asymptomatic *Plasmodium* infections in Narino, Colombia.
1522 Malar J. 2020;19(1):42. doi: 10.1186/s12936-020-3128-9.